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Abstract 
The best known correlate of protection provided by vaccines is the presence of 
pathogen specific antibodies after immunization. However, against the Human 
Immunodeficiency Virus-1 (HIV-1) the mere presence of antibodies specific for the viral 
Envelope (Env) protein is not sufficient to provide protection. This necessitates in depth 
study of the humoral responses elicited during infection and by vaccination. While a 
significant amount of effort has been invested in studying the evolution of antibody 
responses to viral infection, only limited progress in understanding antibody responses 
elicited through vaccination has been made. In the studies described here, I attempt to 
rectify this deficiency by investigating how the quality of a humoral response is altered 
with the use of different immunization regimens, in particular a DNA prime-protein boost 
regimen, or with the use of different model HIV-1 Env gp120 immunogens. In a New 
Zealand White (NZW) rabbit model, we demonstrate that the broader neutralizing 
activity elicited with the DNA prime-protein boost regimen may be the result of the 
elicitation of a higher avidity antibody response and a unique profile of antibody 
specificities. Specifically, use of a DNA prime-protein boost regimen elicits antibodies 
targeted to the CD4 binding domain of the HIV-1 Env, a specificity that was not 
frequently observed when only protein based immunizations were administered.  
We extended this analysis to sera from healthy human volunteers who 
participated in early phase HIV vaccine trials utilizing either a protein alone 
immunization regimen, a canarypox prime-protein boost immunization regimen, or a 
DNA prime-protein boost immunization regimen. Evaluation of sera from these trials 
demonstrated that the use of a DNA prime-protein boost regimen results in an antibody 
 vi
response with greater neutralization breadth characterized by an increased frequency and 
titer of antibodies targeted toward the CD4 binding site (CD4bs). In addition to this, the 
antibody response elicited by the DNA prime-protein boost regimen also exhibited the 
capability to mediate antibody dependent cell-mediated cytotoxicity (ADCC) activity as 
well as activation of the complement system.  
Additionally, in an attempt to better understand the capabilities of antibodies 
elicited by a DNA prime-protein boost regimen, we generated gp120 specific monoclonal 
antibodies (mAbs) from a single DNA primed-protein boosted NZW rabbit. Analysis of 
mAbs produced from this animal revealed that use of this immunization regimen elicits 
an antibody repertoire with diverse epitope specificity and cross reactivity. Furthermore, 
these select mAbs are capable of neutralizing heterologous HIV isolates. Further 
application of mAb generation in rabbits may provide a valuable tool to study 
immunogenicity of different vaccines and immunization regimens.    
Concurrently, while demonstrating that a DNA prime-protein boost regimen 
elicits a higher quality antibody response than that observed with other leading 
techniques, we also demonstrated that immunogen selection can play a vital role in the 
quality of the resulting antibody response. By immunizing with two closely related but 
phenotypically distinct model gp120 immunogens, known as B33 and LN40, we 
demonstrated that disparate gp120s have different intrinsic abilities to raise a 
heterologous neutralizing antibody response. Additionally, we showed that residues 
found within and flanking the b12 and CD4 binding sites play critical roles in modulating 
neutralizing activity of sera from animals immunized with LN40 gp120, indicating that 
 vii
the broader neutralizing activity seen with this immunogen may be due to differential 
elicitation of antibodies to this domain. 
 viii
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Chapter I  
Introduction 
Acquired Immunodeficiency Syndrome (AIDS) remains one of the largest human 
epidemics affecting the world today.  More than 33 million people are currently living 
with Human Immunodeficiency Virus Type 1 (HIV-1), and spread of this virus is 
continuing with an estimated 2.5 million new infections occurring in 2007.  To date, 20 
million deaths have been attributed to HIV-1 infection (2).  The best hope of controlling 
this epidemic is through the development of a successful prophylactic vaccine.  Recent 
setbacks from the STEP trial (17), which relied purely on the induction of cell-mediated 
immune responses, further highlights the need to develop vaccines that can elicit 
protective antibodies, such as neutralizing antibodies,  against primary HIV-1 isolates.  
Unfortunately, eliciting a strong neutralizing antibody (NAb) response to the virus has 
proven to be an exceptionally difficult task.  
Importance of antibodies for vaccines 
The implementation of vaccination to protect a population against acquired 
disease has been one of the greatest successes of modern healthcare. Since Edward 
Jenner’s discovery of vaccination to prevent smallpox, we have striven to utilize and 
manipulate immunological memory through vaccination in order to reduce severity, or in 
some cases, such as smallpox, the existence of a disease causing pathogen altogether. 
While understanding the exact protective mechanisms provided by vaccines remains an 
ongoing process, our best correlate of protection to date is the elicitation of pathogen 
specific antibody responses.   
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Using pox viruses as a model pathogen to study the necessity of antibody 
responses for protection, evidence indicates that virus specific antibodies are both 
absolutely necessary and sufficient for protection from viral acquisition (30). In this 
study, B and T cell populations were depleted from rhesus macaques before vaccination 
with the licensed smallpox vaccine, DryVax. Depletion of the CD8+ cell population had 
no effect on the monkeys’ ability to fight off a subsequent viral infection. Depletion of B 
cells before vaccination, however, resulted in rapid disease progression and death. 
Subsequently, both CD4+ and CD8+ were depleted 6 months after vaccination to assay 
their necessity in the memory response. Again, it was observed that T cell depleted 
macaques were resistant to viral infection, thus providing additional evidence that virus 
specific antibodies were the major protective component of the immune response. 
The protective role of antibodies is not limited to pox viruses. Protective antibody 
responses have also been described against bacterial pathogens, toxins, and other viruses. 
These include but are not limited to Haemophilius influenzae (50), Neisseria meningitides 
(23), Streptococcus pneumoniae (14), diphtheria toxin (69), tetanus toxin (36, 98), 
hepatitis B virus (49), polio virus (35), and influenza virus (82). With such a strong 
historical precedent, it appears highly probable that any protective immune response 
against HIV will require virus specific antibodies as a major component. Despite this 
precedent however, until recently, much of the work on HIV vaccines had moved away 
from inducing a protective antibody response.  
T cell HIV vaccines  
In recent years, the focus of the HIV vaccine field has largely been on the 
induction of strong cell mediated immune responses against the virus. This is especially 
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true for the large effort put forth in inducing strong cytotoxic T lymphocyte (CTL) 
responses directed against the virus.   
Focus on the induction of CTL responses was driven by a number of discoveries 
implicating CD8+ T cells as vitally important in the prevention and control of viral 
infection. Early work on the role of CTL responses in viral infection determined that the 
induction of CTLs is the primary correlate for the control of viremia in early infection 
(15, 53).  These findings were corroborated with the discovery that CD8+ T cells were 
absolutely required to control SIV infection (95). Additional evidence in human patients 
capable of controlling viral replication without therapy, so called “elite controllers”, 
supported this notion further when strong and effective CTL responses correlated with 
viremic control in these individuals (11, 81).   
The theory behind the design of a T cell vaccine is that the presence of a strong 
and immediate CTL response present at the time of viral exposure would, at a minimum, 
reduce chronic viral loads in infected individuals by reducing acute viremia.  This theory 
was supported by data indicating that strong CTL responses were shown capable of 
protecting against viral infection in SHIV protection models (4, 7, 97). Because of the 
success in raising strong T cell responses and the protection seen in SHIV challenge 
models, the T cell vaccine appeared to be an attractive platform for vaccine development.  
However, despite this success in raising strong T cell responses and the protective 
capabilities of the vaccines when facing SHIV challenges, the effect of these vaccines on 
more highly pathogenic SIV challenges was much less substantial (20, 59).   Therefore, it 
is unfortunate, but not entirely surprising, that T cell based vaccines, as shown in the 
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STEP trial, despite being safe and immunogenic in humans, ultimately proved ineffective 
in the best of cases and possibly detrimental in the worst (1, 17, 54, 74, 104).   
Antibodies against the HIV Envelope 
While there will be continued effort to improve the magnitude and breadth of T 
cell responses in future HIV-1 vaccine development, the failure of the STEP trial has 
resulted in a renewed focus on the induction of humoral responses to HIV-1 as a means to 
provide an early, and possibly even sterilizing immune response. The induction of a 
strong functional antibody response, such as in the form of broadly NAbs, is currently 
one of the most sought after goals in the field of HIV-1 vaccine development. 
Unfortunately, HIV-1 contains an array of protective mechanisms that makes the 
elicitation of a broad and potent NAb response an exceptionally difficult task.  Much of 
the difficulty in raising functional antibody responses can be attributed to the high degree 
of diversity found in the envelope (Env) glycoprotein, the major target of NAbs to the 
virus (52).  In addition to the difficulty in overcoming high levels of sequence diversity, 
functional NAbs must also be able to overcome a series of intrinsic defenses present in 
the HIV-1 Env.  This includes high levels of glycosylation, epitope masking by variable 
loops, cryptic binding domains, the high degree of entropy present in the Env protein, and 
masking of functionally important domains by quaternary interactions resulting from 
trimerization of the Env complex (75). Additionally, because HIV, as a retrovirus, 
integrates into the host cell’s genome, there exists only a very narrow window for NAbs 
to act before the establishment of a persistent infection. 
Despite all of the protective mechanisms the virus utilizes, a number of 
monoclonal antibodies (mAb) have been identified that are capable of neutralizing a 
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relatively wide number of primary isolates (13, 18, 124). Study of these antibodies is 
especially important because it reveals weaknesses in the viral Env that can be exploited 
by the immune system to prevent viral infection.  Five of these antibodies, 2G12, b12, 
PG9, PG16, and 447-52D recognize gp120, the surface subunit of Env.  The first of these, 
2G12, targets a cluster of carbohydrate moieties on the heavily glycosylated “silent face” 
of gp120 (92, 93). The mAb b12 binds to a region that overlaps the CD4 binding site 
(CD4bs) (122). PG9 and PG16 are two recently discovered antibodies that most 
efficiently recognize an epitope present on the trimeric form of Env (110). These two 
antibodies recognize a conformational epitope consisting of residues in the V2 and V3 
regions of gp120. The fifth antibody, 447-52D, binds to the tip of the V3 loop of gp120 
and has been shown to have some neutralization breadth against clade B viruses (39). 
Unfortunately, this region is frequently masked upon trimerization of the Env, often times 
limiting both the breadth and potency of other antibodies targeted to this region (79).    
Other broadly neutralizing mAbs, 2F5, Z13, and 4E10, target the membrane proximal 
external region (MPER) of gp41 (72, 126).  
 To date, the only means of providing sterilizing immunity has been the passive 
transfusion of these mAbs before or shortly after viral challenge (24, 31, 45-47, 64, 66).  
The success of these studies demonstrates that sterilizing immunity based on an antibody 
mediated mechanism is indeed feasible, and strengthens the argument for the generation 
of an antibody based HIV vaccine. 
Novel immunization modalities for raising HIV specific humoral responses 
Unfortunately, until very recently, there was little progress made in the pursuit of 
an antibody based vaccine that prevented HIV infection. The most prominent setbacks 
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were the failed phase III Vaxgen trials (33, 80). These trials employed a traditional 
subunit based vaccine consisting of gp120 adjuvanted in alum. While these trials were 
very successful in raising binding antibodies, and even NAbs against autologous T Cell 
Line Adapted (TCLA) strains of HIV, they did not succeed in generating a heterologous 
NAb response against relevant primary isolates and, ultimately, did not prevent HIV 
infection. Since these results became public, it became apparent that a large effort needed 
to be put forth to raise the quality of the antibody response generated through 
immunization. One of the primary means by which researchers have attempted to do this 
is to experiment with novel methods of immunization, including DNA vaccines, HIV 
proteins delivered in a viral vector, and heterologous immunization regimens that deliver 
the same immunogen, but deliver it via two different methods. This last method, a 
heterologous prime-boost regimen, is arguably the most interesting given that its use has 
been reported to provide partial protection against HIV acquisition in a phase III trial, 
RV144, the details of which will be discussed shortly.   
Viral vector based vaccines 
One novel approach that has been tested in the HIV vaccine field is to use viral 
vectors to deliver HIV-1 antigens. One such application of this approach has been 
evaluated in a phase I human trial using an adenovirus vector to deliver HIV-1 Env 
antigens (21). This study used an adenovirus delivery system that was made replication 
incompetent through the deletion of the E1, E4 and part of the E3 regions of the viral 
genome.  Genes encoding a gag-pol fusion protein were inserted into the virus, intended 
for elicitation of T cell responses, as well as three gp140 Env genes, each derived from a 
single clade A, clade B, and clade C isolate. Four weeks after immunization, 93% of 
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individuals were capable of recognizing the homologous clade B Env by IP-Western blot. 
When antibody responses were measured by ELISA however, only 50% of the 
individuals were capable of recognizing one of the three antigens used in the vaccine 
formulation. Despite the positive binding titers induced in some individuals, no 
neutralizing activity was detected against the highly sensitive isolate SF162, or the TCLA 
isolate HXB2. Therefore, while this vaccine proved to be relatively safe, it failed to 
generate a highly immunogenic humoral response against even highly sensitive HIV-1 
viruses.  
The use of a canarypox virus to deliver HIV antigens has also been evaluated 
(91). In this phase II human trial, uninfected individuals were immunized with the 
canarypox vector vCP1452, encoding the gp120 protein of MN fused to the gp41 region 
of the HIV isolate LAI, plus the entire gag gene and CTL epitopes derived from the nef 
and pol proteins. The canarypox immunization was either administered alone, or boosted 
with a subunit protein consisting boost of a bivalent formulation of gp120s derived from 
the HIV-1 isolates MN and GNE8 for a total of four immunizations. Positive binding 
antibodies were raised against the gag protein in 23-36% of individuals depending on the 
immunization group. More relevantly however, between 70% and 83% of individuals 
raised NAb responses against the homologous isolate MN. Notably, individuals that 
received only canarypox based immunizations elicited lower titers of NAbs against MN. 
Neutralization of the heterologous isolate IIIB was also evaluated in a limited number of 
samples. When heterologous neutralization was taken into account, those individuals who 
received only the canarypox based immunization fared significantly worse than those 
who received a subunit protein booster. Specifically, the individuals who received only 
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canarypox immunizations never successfully neutralized IIIB, while individuals who 
received a subunit protein boost were able to neutralize the virus in 70% of cases. The 
generation of antibody responses capable of neutralizing TCLA strains of virus using a 
similar canarypox prime-protein boost immunization regimen has also been mirrored in a 
number of other studies, demonstrating the utility of a heterologous prime-boost regimen 
(10, 32, 41, 105). 
DNA vaccines 
The use of DNA vaccines to raise humoral responses against HIV-1 was first seen 
in the early nineties where it was shown that a DNA plasmid encoding HIV-1 Env 
derived from a TCLA isolate was capable of raising HIV-1 specific antibody responses in 
small animals (62, 111). The antibodies raised by this approach were capable of binding 
recombinant Env protein as well as neutralizing the HIV-1 isolate IIIB.  The utility of this 
approach was further demonstrated in a SHIV challenge model in cynolomogous 
macaques (16). In this study, animals that received DNA immunizations generated a 
strong immune response that, upon viral challenge, resulted in a decreased viral load 
compared to unimmunized animals. Furthermore, in this study, one of four immunized 
animals was protected from viral challenge upon completion of the DNA immunization 
regimen.  
 Other than a DNA vaccine’s obvious ability to generate an immune response, 
there are a number of positive aspects that make DNA based immunizations an attractive 
option for use as a platform for an HIV-1 vaccine. The first of these is the endogenous 
production and processing of a chosen antigen. When a DNA immunization is given, 
antigen encoding plasmids are taken up directly by cells at the injection site of the host, 
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thereby making antigen production similar to that of a live attenuated vaccine. This 
allows the protein to undergo well regulated translation processes, allowing for native 
folding, as well as normal post translational modifications, such as glycosylation, of the 
antigen of interest. Additionally, because of the endogenous production of the antigen, 
the produced protein can be efficiently presented to the immune system through class I 
and class II MHC complexes, allowing for an efficient T cell response to the antigen. In 
addition to native antigen production and processing, the DNA vaccine has also proven to 
be a very safe alternative to subunit and live attenuated vaccines (19, 63, 90, 107, 112). 
Because DNA vaccines are normally non-replicative, non-integrative, and can only 
encode the protein(s) of interest, DNA vaccines allow the researcher to elicit an antibody 
response with the specificity of a subunit vaccine and the native antigen processing of a 
live attenuated vaccine, all without the safety risk of reversion of an attenuated viral 
strain into a more pathogenic one. 
In addition to its relative safety, DNA based immunizations provide an excellent 
platform for studying different properties of a particular antigen, screening of different 
immunogens (71, 88), identifying immunogenic and neutralizing domains of a target 
(114), as well as identifying effective immunization regimens (89). 
Unfortunately a number of caveats still exist that prevents the widespread 
application of this technique. One of these caveats is the relatively low in vivo 
transfection efficiency. The inefficient uptake of the DNA plasmid by host cells leads to 
low levels of in vivo antigen production.  Because of this, a significant effort has been 
applied to increase the potency of DNA vaccines. This includes studying different 
delivery mechanisms for the DNA itself. These methods include electroporation (44, 
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119), needle free jet systems (3, 42, 106), gene gun (106, 119), and microneedle 
injections (83), all of which are intended to increase the efficiency of DNA delivery over 
a traditional intramuscular injection (119).  
Increasing the efficiency of DNA delivery is only one aspect in the effort to 
increase the potency of DNA immunizations. Work has also focused on the design of the 
DNA constructs themselves in order to enhance antigen production on the level of the 
individual transfected cell. One of the primary improvements that has been made is the 
advent and implementation of codon optimization to maximize the efficiency of tRNA 
usage in the cell (27, 115, 125). Optimizing each codon to utilize the most prevalent 
tRNA present in the cell allows for more efficient protein translation, resulting in a higher 
quantity of antigen being produced. Other work to increase the amount of antigen 
produced has focused on manipulating the leader sequences and promoters of these 
constructs (115). Here, it was demonstrated that simultaneous manipulation of the 
immunogen leader sequence, promoter, and codon usage resulted in improved 
immunogenicity of a gp120 protein in a mouse model (115). 
Despite some of these limitations, the ease of use and safety of DNA vaccines has 
lead to the evaluation of these vaccines in human clinical trials in attempts to raise HIV-1 
specific antibody responses. In one trial, three DNA immunizations encoding three Env 
antigens from clades A, B, and C, as well as the T cell antigens, gag, pol, and nef, were 
given to healthy human volunteers using a needle free injection system (22).  Antibody 
responses from this trial were then evaluated by ELISA and neutralizing antibody assays. 
Humoral responses recognizing the clade A and C Envs were generated in 71% of 
individuals with the clade B being recognized in 64% of individuals in the trial. Despite 
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the presence of binding antibodies, none of the vaccinated individuals generated NAbs 
against even the sensitive HIV-1 isolate, MN. This indicates that use of an immunization 
regimen consisting of a DNA vaccine alone may not be immunogenic enough to provide 
a protective response.  
This pattern of raising a binding antibody response but not a Nab response has 
been observed in other DNA only vaccine trials as well. One such trial delivered DNA 
encoding a gag-pol-nef fusion protein plus modified Env constructs derived from clades 
A, B and C via a needle free injection system (40).  Similar to the previous DNA only 
trials, binding antibodies, as determined by ELISA, were raised in 60% of individuals. 
Again, however, a total lack of NAb responses were raised against the sensitive HIV-1 
isolate, MN. A third trial, utilizing only DNA-based immunizations encoding gag, pol, 
env, rev, tat, and vpu, delivered by a needle based intramuscular injection, also failed to 
produce any detectable NAb responses against the HIV-1 isolates ADA or MN (70). As a 
whole, these trials have highlighted the fact that, in humans, neither DNA based nor viral 
vector based immunization platforms are immunogenic enough on their own to become a 
viable vaccine.  
Heterologous prime-boost vaccine regimens 
 In summary, the use of a single modality immunization has produced less than 
stellar humoral responses in HIV clinical trials in humans. Although several traditional 
and novel vaccine types have been tested, each appears to have their shortcomings. While 
traditional subunit protein was shown to be immunogenic, it was not protective. DNA 
and viral vectored vaccines, on the other hand, were overall not immunogenic enough to 
generate a robust response. The question that now remains is whether or not higher 
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quality antibody responses can be generated through the combination of different 
immunization regimens relative to their use alone. 
DNA vaccine prime-viral vector boost  
 Based upon the limited ability of vaccines utilizing a single modality to raise an 
effective antibody response against HIV-1, combinations of heterologous immunization 
approaches have also been attempted. One such study used a DNA prime and adenovirus 
boost to elicit cellular and humoral immunity in rhesus macaques (65). In this study 
immunization of rhesus macaques with a chimeric HxBc2/BaL gp145 construct delivered 
either by a DNA prime-adenovirus boost or strictly repeated immunizations with 
recombinant adenovirus type 5 (rAd5) was evaluated.  Immunization with a single Ad5 
vector generated higher binding titers against the gp140 protein compared to 
immunization with only DNA vaccine. However, repeated boosting of the rAd5 
immunized animals with additional rAd5 virus did not enhance the antibody response.  In 
contrast, if a DNA prime was given to the animals prior to a rAd5 boost, a rapid rise in 
Env antibody binding titers were observed. Neutralizing activity raised by the two 
immunization approaches was also evaluated. Neutralization of the 89.6 isolate was 
found to be significantly greater in animals that first received a DNA prime prior to 
adenovirus boosting, indicating the superiority of this combination immunization 
approach relative to immunization with only rAd5. However, the breadth of 
neutralization using the DNA prime rAd5 boost format was still somewhat limited, with 
only about a third of tested clade B isolates being neutralized by sera generated from 
immunization with either an 89.6 or chimeric HxBc2/BaL construct. 
Canarypox prime-protein boost 
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In the phase II canarypox prime-protein boost trial discussed above (91), the 
authors demonstrated that using the heterologous prime-boost regimen elicited a 
significantly higher and broader NAb response than immunization with only the 
canarypox vector. This work was continued further by evaluating a canarypox prime-
protein boost regimen in a large phase III trial known as RV144 (85). This trial is 
interesting for several reasons, with the primary reason being that it is the first HIV 
vaccine trial ever to provide partial protection from HIV acquisition. In a modified intent-
to-treat group, the authors report a statistically significant, 31% drop in HIV acquisition 
compared to a placebo controlled group. The second interesting point is that this trial 
used two pre-existing products that alone were either not very immunogenic, as was the 
case for the canarypox vaccine (91), or did not provide any protective capacity as was 
observed with the AIDSVAX B/E protein vaccine (80). However, the observation that, 
when combined, this vaccine can provide partial protection is a remarkable result. While 
the exact mechanism of this protection remains unclear, it provides additional evidence 
that suggests that the combination of two different immunization regimens can provide a 
higher quality immune response than either immunization regimen can alone. The 
relative success of this trial may provide a glimpse of the power of heterologous prime-
boost regimens, and justifies further investigation into, not only canarypox plus protein 
combinations, but other heterologous prime-boost immunizations as well.  
DNA prime-protein boost 
Our group has been working with a heterologous prime boost regimen, the DNA 
prime-protein boost regimen, for nearly fifteen years. We and others have shown, in 
historical data covered here, in original data presented later, and in agreement with the 
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recent RV144 trial, that a heterologous prime-boost regimen elicits a higher quality 
humoral response than immunization with either modality alone.  
Despite improvements in the design of the DNA construct and the increase in 
efficiency in the delivery, DNA immunizations are still only capable of producing limited 
quantities of antigen at levels much lower than those produced by inactivated or subunit 
vaccines. Because of this, as witnessed in DNA vaccine alone human HIV-1 trials, this 
vaccination modality is not immunogenic enough on its own to generate an effective 
antibody response against the virus when delivered by a traditional needle injection.  
Despite this, DNA immunizations are highly effective in priming the body’s immune 
system and work best when used in combination with another immunization approach, 
usually with DNA administered as a priming immunization followed by a boost of other 
modality. One of the simplest and most effective of these combination approaches for the 
elicitation of humoral immunity is a DNA prime followed by a subunit protein boost 
(60).   
Early studies using the DNA prime-protein boost approach utilized TCLA derived 
Env proteins in the vaccine formulation (87). Rabbits in this study were immunized with 
DNA based immunizations encoding gp120, gp140, or a replication incompetent form of 
HXB-2 and subsequently boosted with rgp160 derived from the HIV-1 isolate IIIB in 
Incomplete Freund’s adjuvant (IFA). While only limited binding antibodies were 
generated following DNA immunization, boosting with recombinant protein greatly 
increased binding titers in immunized animals. Analysis of serum avidity elicited by each 
immunization regimen indicated that use of a combination approach elicited a higher 
avidity antibody response than that which was observed with the use of DNA 
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immunizations alone. In addition, the combination DNA prime-protein boost approach 
generated significantly greater homologous NAb titers than that observed with 
immunization of naïve animals with only recombinant protein. Heterologous NAb 
responses against MN and SF2 were also generated using this prime boost immunization 
regimen. Titers in immunized animals varied from 1:148 to exceeding 1:3000 against 
MN and 1:37 to 1:269 against SF2.  
Initial work demonstrated that a DNA prime-protein boost strategy is an effective 
means by which to raise antibody responses in both small animals and non-human 
primates (6, 55). However, many of these studies suffered from the inability to neutralize 
the more relevant primary isolates of HIV-1.  One breakthrough study, in an attempt to 
overcome the limitations of TCLA derived immunogens, used gp120 derived from the 
primary isolate JR-FL as a model immunogen (113).  In this study, rabbits were 
immunized in either a DNA prime-protein boost format, or with only recombinant gp120 
protein derived from the primary isolate JR-FL. Sera generated by both immunization 
approaches contained high levels of binding antibody to homologous envelope, but the 
NAb response generated by each immunization regimen differed dramatically. One 
example of this was observed with the neutralization of the sensitive isolate SF162. Both 
immunization regimens were capable of generating a Nab response against this sensitive 
isolate, however, the DNA primed animals did so with a much higher titer. Additionally, 
animals that received a DNA prime were capable of neutralizing the homologous strain 
of HIV-1, JR-FL, in a PBMC based neutralization assay.  Inhibition of this neutralization 
resistant primary isolate was not observed in animals that were immunized with only 
protein. Sera raised by the DNA prime-protein boost approach were also frequently 
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capable of neutralizing other heterologous clade B isolates, including 1196 and 0692, a 
phenomenon that was absent in animals that received only protein based immunizations.  
The superiority of the DNA prime-protein boost approach was proven again 
concurrently in a separate study looking at the effect of oligomerization state on the 
elicitation of NAbs (8).  Here, the use of a DNA prime-protein boost approach elicited a 
12-fold higher binding antibody response when compared to immunization with only 
protein, clearly demonstrating the potential of this platform for eliciting an antibody 
response to the virus. This increase in binding titer was accompanied by a slight increase 
in the frequency of neutralization of the autologous JR-FL virus between vector primed 
and trimer primed animals.  
While the DNA prime-protein boost approach was able to enhance the binding 
and neutralizing antibody response elicited when compared to immunization with subunit 
protein alone, the overall breadth of neutralizing activity was still somewhat limited. The 
most likely explanation for this was the use of only a single, subtype B Env in the vaccine 
formulation. One attempt to increase the breadth of the neutralizing activity was to 
include multiple, genetically distinct Envs into a single polyvalent formulation (118). In 
this study, rabbits were immunized in a DNA prime-protein boost format consisting of 
either monovalent or polyvalent formulations of gp120 derived from clades A, B, C, D, 
E, F, and G. Sera generated by immunization with these constructs were then tested in a 
pseudovirus based neutralization assay against a panel of 14 viruses from clades A-E. 
Data from this study revealed that immunization with a polyvalent Env formulation 
significantly increased the breadth of neutralization against this multiclade panel of 
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pseudoviruses, as evidenced by an almost doubling in the number of isolates neutralized 
compared to the monovalent immunization groups (118). 
The success of the DNA prime-protein boost immunization regimen further 
demonstrated its promise in non-human primate studies. To this extent, a modification of 
the polyvalent formulation above, consisting of two clade B gp120s, one clade C gp120, 
and one clade E gp120, plus gag derived from NL4-3 was tested for its protective 
efficacy in rhesus macaques (73). Animals received a combination of DNA and protein 
based immunizations and were subsequently rectally challenged with the R5 SHIV BaL. 
At the time of challenge, immunized animals had generated an antibody response capable 
of neutralizing the sensitive isolates of HIV, MN and SF162, as well as the BaL 
challenge strain. Immunization with the above regimen protected four out of six 
macaques from infection with the SHIV, based upon detection of viral RNA in the blood 
(a sterilizing immunity). Relative to a control group of seven naïve animals who all 
became infected and demonstrated high viral loads, the remaining two immunized 
macaques that became infected demonstrated lower levels of viral RNA in the blood. 
Because the gag antigen is from an HIV-1 isolate, while the macaques were challenged 
with a SHIV whose gag antigen is derived from SIV, the protection is likely mediated by 
Env-induced immunity, most likely due to anti-Env antibodies. 
Other studies have also confirmed the utility of the DNA prime-protein boost 
approach in non-human primates. One of these studies used this prime-boost approach in 
neonatal macaques (84). Immunization of animals in this study with DNA encoding vpu 
and the IIIB Env, followed by boosting with recombinant IIIB derived gp160, protected 
out of 15 animals from a homologous IIIB intravenous SHIV challenge. Another study 
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utilizing the DNA prime-protein boost approach immunized rhesus macaques with gp120 
or gp160 forms of envelope derived from HXBc2 (55). Homologous NAb titers 
exceeding 1:1000 were generated as a result of immunization with these constructs. 
Following an intravenous challenge of SHIV HXBc2, none of the immunized monkeys 
became infected based as evidenced by an inability to re-isolate the challenge HXBc2 
virus at every bleed after challenge. 
As a result of data demonstrating that a DNA prime-protein boost approach could 
provide sterilizing immunity in a SHIV protection model, the DNA prime-protein boost 
approach was tested in a Phase I clinical trial (117). Again, a polyvalent Env formulation 
was used, this time consisting of five Envs from clades A, B, C, and E.  After three DNA 
immunizations and two protein boosts, humoral responses were evaluated using solid 
phase antibody binding and NAb assays. Immunization with this polyvalent Env vaccine 
formulation and regimen elicited broad and high titer binding antibody responses against 
gp120 antigens from clades A through H of HIV-1 in all individuals enrolled in the trial 
when evaluated by ELISA and Western blot analysis.   Additionally, NAb responses were 
detected in 100% of individuals against the sensitive HIV-1 isolates MN, NL4-3, and 
SF162 at titers as high as 1:2000.  Neutralization of the homologous primary isolates 
included in the vaccine was also frequently observed.  Specifically, neutralizing activity 
was detected in more than 60% of individuals against the subtype C vaccine strain 
96ZM652.  In addition to eliciting NAbs against sensitive and homologous isolates, a 
result not always observed in previous trials, the new polyvalent DNA prime-protein 
boost regimen also generated neutralizing activity against difficult to neutralize 
heterologous primary isolates from clades A, B, C, D, and E in the high throughput 
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pseudovirus based PhenoSense neutralization system (117).  Positive NAb responses 
were identified in each of the 22 vaccines included in the analysis with about 60% of 
vaccinees having positive NAb responses against 80-100% of pseudotyped viruses 
included in the assay.  This represents a significant improvement over the NAb responses 
reported with immunization via protein, DNA, or viral vectors alone as well as 
combinations of viral vector prime-protein boost and DNA prime-viral vector boost 
vaccines. In addition to strong NAb responses, this DNA prime-protein boost regimen 
also elicited a polyfunctional T cell response (5). This is important to note because, 
despite the setback from STEP, it is still highly probable that a balanced B and T cell 
response will be required to provide the best possible protection against HIV. 
Additionally, while this vaccine was successful in generating a cross reactive antibody 
response, it also proved to be safe and well tolerated (51).  
Research Framework and Objectives 
The previous data described above laid the foundation for the original body of 
work described herein. While it has become increasingly accepted that use of the DNA 
prime-protein boost regimen elicits a higher quality antibody response than immunization 
with only protein, the underlying mechanism of this phenomenon remains unclear. The 
work described in the following chapters attempts to identify specific attributes of the 
humoral response resulting from a DNA prime-protein boost immunization regimen that 
may account for the higher quality NAb activity observed when this regimen is used.  We 
attempt to identify the role of the DNA and protein components in the priming and 
boosting phases of an immunization regimen in contributing to the final antibody 
response. We expand this analysis using a second antigen formulation and identify a 
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unique profile of antibody specificities resulting from immunization with a DNA prime-
protein boost regimen in small animals.  We extend this characterization to human serum 
samples resulting from immunization with a protein alone regimen, a canarypox prime-
protein boost regimen, and a DNA prime-protein boost regimen, thus allowing us to 
determine if the patterns we identify in small animals are also seen in healthy, immunized 
humans.  
Also, using the DNA prime-protein boost regimen as a tool, we attempt to 
demonstrate that individual gp120 immunogens have different capabilities of raising a 
heterologous NAb response and that the broader NAb response elicited by select gp120s 
is due to recognition of conserved domains on the HIV Env. 
Finally, in order to allow us to directly compare the capabilities of antibodies 
elicited through immunization to those elicited through infection, we generate HIV 
specific mAbs from a single DNA primed-protein boosted rabbit. 
 21
Chapter II 
Analysis of the quality of antibody responses elicited by immunization with DNA, 
protein, or DNA plus protein 
Introduction 
Previous data from our lab has indicated that gp120 formulations delivered by a 
DNA prime-protein boost approach are capable of eliciting an antibody response with the 
ability to neutralize isolates from many of the major subtypes of HIV (117, 118). 
Additional data in the NZW rabbit model has indicated that the combination DNA prime-
protein boost regimen elicits a broader NAb response than immunization with only 
protein (Fig 2.1). However, the underlying mechanism driving this phenomenon 
remained unclear. 
The previous studies that first noted this phenomenon lacked several controls that 
would have helped elucidate this phenomenon further. In this chapter, we attempt to 
address these shortcomings by making a more stringent comparison between humoral 
responses elicited by different immunization regimens. In order to accomplish this, 
rabbits were immunized in one of five different ways using JR-FL gp120 as a model HIV 
antigen. The first two methods of immunization repeat the regimen used in previous 
studies (117, 118). The first of these is the delivery of three DNA empty vector 
immunizations followed by two protein immunizations in IFA. The second employed 
three DNA primes with a JR-FL gp120 construct followed by two protein boosts with 
recombinant JR-FL gp120 protein. A direct comparison between these groups allows us 
to control for any nonspecific effects of the DNA priming. However, there remains a  
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Fig 2.1. Neutralization breadth of sera resulting from immunization with either a DNA 
plus protein or a protein alone regimen. Pie charts demonstrating the capability of serum 
from animals immunized with either a DNA plus protein regimen or a protein alone 
regimen to neutralize a panel of HIV isolates. Grey shaded regions indicate the 
percentage of viruses from a 14 virus panel capable of being neutralized by sera from 
each immunization regimen. Figure adapted from (118). 
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large caveat with this comparison, this being that the vector prime-protein boost group 
only receives two immunizations that contain antigen, while the JR-FL DNA prime-
protein boost received five immunizations containing antigen. In order to address this, in 
the current study, we included an additional control consisting of a group of rabbits that 
received five JR-FL protein immunizations. This allowed us to directly answer the 
question of whether three additional protein immunizations could increase the breadth of 
the NAb response.  
The next control that was lacking in the previous study is the presence of a five 
DNA immunization group. Inclusion of this control would have allowed us to evaluate 
whether a DNA immunization is the primary determinant of the specificity of the final 
immune response, whether it elicits a unique profile of antibody specificities itself, or 
whether a combination of the DNA and protein plays a unique role in determining the 
final antibody profile.  
A third control that would have been interesting for inclusion in the previous 
study is one where the priming and boosting antigens were not precisely matched. This 
mismatched antigen regimen could result in a broader recognition of HIV antigens 
compared to a matched antigen regimen due to the exposure of B cells to greater 
sequence diversity. 
In the current study, with the inclusion of these additional controls to address 
missing elements of the previous work, we monitored the effects of different 
immunization regimens on the resulting antibody response. We evaluated differences in 
antibody binding titer, specificity, neutralizing activity, and avidity elicited by each of  
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these regimens and identified a unique profile of antibody characteristics elicited when a 
DNA component is included in the immunization regimen. 
Results 
In this study, rabbits were immunized in one of five schedules in order to provide 
a direct comparison as to the relative immunogenicities of homologous vs. heterologous 
prime-boost vaccinations.  These approaches (summarized in Fig 2.2) utilize HIV-1 JR-
FL gp120 as a model antigen delivered as either a DNA vaccine or a recombinant protein 
vaccine. 
 Groups of NZW rabbits were immunized with one of the following regimens: 1) 
five JR-FL gp120 DNA immunizations; 2) five JR-FL gp120 protein immunizations; 3) 
three JR-FL gp120 DNA immunizations followed by two JR-FL gp120 protein 
immunizations.  The first two schedules are homologous prime-boost using the same type 
of vaccine.  The third schedule is a heterologous prime-boost regimen which 
administered DNA and protein immunizations to the same animals at different time 
points.  Consistent with previous studies, three DNA-based immunizations were given in 
the priming phase, followed by two protein-based immunizations in the boosting phase 
(108, 117).  Two additional immunization schedules were included as controls. In one 
schedule, rabbits received three empty DNA vaccine vector immunizations followed by 
two JR-FL gp120 protein boosts.  The purpose of this control is to exclude the non-
specific effect by a DNA plasmid as the prime.  Another control group received the JR-
FL DNA priming immunizations, but was boosted with a 5-valent gp120 protein vaccine, 
which included the JR-FL gp120 and four other gp120 proteins from clades A, B, C and 
E. Inclusion of this group allowed for the comparison between the polyvalent and  
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Fig 2.2. Study design and immunization schedule for rabbits receiving JR-FL gp120based 
immunizations. Rabbits were immunized with one of five prime-boost regimens: 1) three 
DNA vector immunizations plus two JR-FL gp120 protein boosts; 2) five JR-FL gp120 
protein immunizations; 3) five JR-FL gp120 DNA immunizations; 4) three JR-FL gp120 
DNA immunizations plus two JR-FL gp120 protein boosts; 5) three JR-FL gp120 DNA 
immunizations plus two 5-valent gp120 protein boosts. The 5-valent protein mixture 
consisted of gp120s from clades A (UG21-9), clade B (JR-FL + US715), clade C 
(MW959), and clade E (TH14.12). “Priming” immunizations were administered at 
Weeks 0, 2, and 4. “Boosting” immunizations were given at Weeks 8 and 12.  
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monovalent boosts.  In all of the above studies, the “priming” immunizations were given 
at Weeks 0, 2, and 4 with “boosting” immunizations given at Weeks 8 and 12 (Fig 2.2). 
Generation of gp120 specific antibodies as measured by ELISA 
 The overall immunogenicity for each immunization regimen was first determined 
by measuring the binding titers of serum IgG for each individual rabbit against the JR-FL 
gp120 antigen by ELISA (Fig 2.3).  All rabbits, regardless of immunization regimen, 
generated a significant gp120-specific antibody response.  Despite the observation that 
rabbits receiving five protein immunizations tended to generate a slightly lower binding 
antibody response, endpoint serum dilution titers among these groups were statistically 
indistinguishable from each other.  Additionally, variation of individual animals within a 
single group was also minimal, with no animals deviating more than a single dilution step 
from the group geometric mean titer.  
Analysis of antibody specificity elicited by each immunization regimen 
We chose to use a pseudoviral based competitive binding assay to examine 
antibodies of a particular specificity capable of binding to an HIV-1 viral Env spike as 
previously reported (25, 68, 108).  Knowing that the V3 loop is an immunodominant  
epitope of gp120, whose recognition is sometimes responsible for the neutralization of 
select viruses, we began by assaying sera for the presence of V3 directed antibodies using 
a known V3 directed monoclonal antibody, 447-52D, in a competitive binding assay (Fig 
2.4A).  Consistent with the immunodominant nature of the V3 loop, all immunization 
regimens elicited high titer antibody responses capable of outcompeting binding of 447 to 
this domain.  In many cases, titers approached or exceeded 1:1000.  However, animals 
that received only protein immunizations or immunizations with only the empty DNA  
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Fig 2.3 Endpoint binding titers of sera from rabbits receiving JR-FL based 
immunizations.  Endpoint binding titers from samples collected two weeks after the final 
boosting immunization were determined against the autologous JR-FL gp120 protein by 
ELISA. Immunization groups are abbreviated as follows: three DNA vector 
immunizations plus two JR-FL gp120 protein boosts (3V + 2P), five JR-FL gp120 
protein immunizations (5P), five JR-FL gp120 DNA immunizations (5D), three JR-FL 
gp120 DNA immunizations plus two JR-FL gp120 protein immunizations (3D + 2P), and 
three JR-FL gp120 DNA immunizations plus two polyvalent gp120 protein 
immunizations (3D + 2pP) .   Symbols denote individual rabbits. Bars denote geometric 
mean within a group. 
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Fig 2.4. Specificity of JR-FL based vaccine induced antibody responses as determined by 
mAb competition. The ability of serially diluted polyclonal serum to outcompete binding 
of mAbs to a JR-FL & VSV-G pseudotyped virus was measured. Competition titers 
indicate the serum dilution preventing 50% of pseudoviral binding to the ELISA plate. % 
competition was calculated according to the following equation: % competition = [(RLUs 
in absence of sera – RLU in presence of sera)/RLUs in absences of sera]*100.  A. 
Competition against the V3 directed mAb 447-52D.  B. Competition against the glycan 
directed mAb 2G12.  C. Competition against the co-receptor binding site directed mAb 
17b.  D. Competition against the narrowly neutralizing CD4bs mAb F105. E. 
Competition against the broadly neutralizing CD4bs mAb b12. Immunization groups are 
abbreviated as follows: three DNA vector immunizations plus two JR-FL gp120 protein 
boosts (3V + 2P), five JR-FL gp120 protein immunizations (5P), five JR-FL gp120 DNA 
immunizations (5D), three JR-FL gp120 DNA immunizations plus two JR-FL gp120 
protein immunizations (3D + 2P), and three JR-FL gp120 DNA immunizations plus two 
polyvalent gp120 protein immunizations (3D + 2pP). 
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vaccine vector prime had the lowest V3 loop-targeted antibody responses.  The group 
with the highest antibody responses to this region included rabbits that received the DNA 
prime-protein boost regimen with the matched JR-FL boost.  Rabbits in this group 
elicited a significantly higher V3-directed antibody response than rabbits that received 
five protein-based injections (p=0.02).  Interestingly, the group that received a polyvalent 
gp120 boost had a lower 447-52D-like antibody response than the monovalent (JR-FL 
gp120) boost, suggesting that the polyvalent boost, which included gp120s from different 
subtypes, may dilute the focus of V3 specific antibodies away from subtype B V3 
epitope. 
Next, we expanded our analysis to antibodies against other important gp120 
epitopes. This was conducted by determining any differences in the fine specificity of the 
antibodies elicited by each prime-boost immunization regimen.  First, we looked for the  
presence of antibodies targeted to a cluster of carbohydrates recognized by the human 
mAb, 2G12 (Fig 2.4B).  Of the 15 rabbits tested in this study, only one that received the 
homologous DNA prime-protein boost was capable of outcompeting binding to the mAb 
2G12, indicating that antibodies of this specificity are rare with any of the immunization  
schemes used in the current study. This observation is also consistent with data in HIV 
infected humans, indicating that antibodies of this specificity are rarely elicited (94).
 Next, we evaluated the rabbit immune sera for the presence of antibodies targeted 
to the co-receptor binding site by testing competition with the human mAb, 17b (Fig 
2.4C).  Again, with only a single rabbit capable of outcompeting binding, and at a titer 
barely reaching our cutoff of 50% reduction in binding at a 1:40 serum dilution, we 
determined that antibodies targeted to this domain were also largely absent. This result is 
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also consistent with a previous report showing that the failure to elicit co-receptor-
targeted antibodies in rabbits was not unusual (34). 
The presence of CD4bs specific antibodies in sera from immunized animals was 
also evaluated using either the narrowly neutralizing monoclonal antibody, F105 (Fig 
2.4D), or the broadly neutralizing antibody, b12 (Fig 2.4E).  When the mAb F105 was 
used as a competitive binding target, five of the six animals that received only protein 
immunizations demonstrated no capability of outcompeting binding to this monoclonal 
antibody.  In contrast, all animals that received five DNA immunizations generated 
antibodies capable of outcompeting binding to F105, and did so with the highest 
competition titer among all groups with an average reciprocal dilution of approximately 
150.  Similarly, all three animals in the matched JR-FL DNA prime-protein boost group 
generated an antibody response capable of outcompeting binding to F105. Interestingly, 
when the protein boost formulation was changed from a single JR-FL gp120 to five 
recombinant gp120 proteins from different HIV-1 subtypes, antibodies capable of 
competing binding to F105 were largely absent, with only one of the three animals 
capable of doing so at a lower serum dilution.   
This general trend continued when we tested the ability of the rabbit sera to 
outcompete binding to a second CD4bs mAb, b12, which can neutralize a wide range of 
primary HIV-1 isolates (Fig 2.4E).  Again, the animals that received only two JR-FL 
gp120 protein-based immunizations with the empty DNA vector prime could not 
outcompete binding to b12 in any instance.  Consistent with the F105 competition results, 
animals that received immunizations with only protein only sporadically elicited 
antibodies targeted to the CD4bs. In those sera where competition was detected against 
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b12, it was of very low titer, barely making our cutoff of a 1:40 dilution.  Again, in the 
animals that received five DNA immunizations, we detected CD4bs directed antibodies at 
titers very similar to those observed against F105, at approximately a 1:150 dilution.  
Two out of the three rabbits that received a monovalent DNA prime-protein boost were 
capable of outcompeting binding to b12.  This is one rabbit less than was capable of 
outcompeting binding to F105 within the same group.  However, the two animals that did 
generate antibodies capable of outcompeting binding to b12 did so with high 50% 
competition values approaching serum dilution of 1:600.  In rabbits that received the 
polyvalent protein boost, we again noticed that only one out of the three animals was 
capable of outcompeting binding to b12.  This change in the boost formulation may result 
in the generation of antibodies that recognize the CD4bs of Envs from other clades. If this 
is the case, these non clade B CD4bs Abs may be unable to outcompete binding of the 
largely subtype B-specific antibodies, F105 and b12, to the viral envelope. 
Neutralization of Tier 1 HIV-1 viruses 
 The competition analysis performed above indicated that every immunization 
regimen elicited antibodies to the V3 loop. However, since the ability to outcompete 
binding to V3-directed antibodies only confirms the presence of this type of antibody in 
the immune sera but does not reveal any information about their functionality, we 
evaluated how well these V3-directed antibodies are capable of neutralizing sensitive 
isolates of HIV-1.  In order to do this, we utilized two viruses with a known sensitivity to 
V3-mediated neutralization.  The first virus was SF162 (Fig 2.5A). Consistent with the 
presence of high titer V3-directed antibodies in rabbit sera, this virus was neutralized by 
serum from every animal in the study.  However, the potency at which this was achieved  
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Fig 2.5 Neutralizing activity of sera elicited by different JR-FL based vaccine regimens 
against sensitive HIV isolates. Rabbit sera collected two weeks after the final boost 
immunization were tested for their ability to neutralize Tier 1 sensitive HIV isolates in 
the TZM-bl assay system  A. Serum NAb titers against SF162. B. Serum NAb titers 
against NL4-3.  Neutralization was calculated according to the following formula: % 
neutralization = [(Preimmune RLUs – Immune RLUs)/(Preimmune RLUs)]*100. NAb 
titer is defined as the serum dilution capable of inhibiting 50% of viral infection. 
Immunization groups are abbreviated as follows: three DNA vector immunizations plus 
two JR-FL gp120 protein boosts (3V + 2P), five JR-FL gp120 protein immunizations 
(5P), five JR-FL gp120 DNA immunizations (5D), three JR-FL gp120 DNA 
immunizations plus two JR-FL gp120 protein immunizations (3D + 2P), and three JR-FL 
gp120 DNA immunizations plus two polyvalent gp120 protein immunizations (3D + 
2pP). 
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differed between immunization groups.  Geometric mean NAb titers in groups whose 
immunizations consisted of only a single vaccine modality were all below 1:100.  
Specifically, geometric mean NAb titers for animals that received two protein, five 
protein, or five DNA immunizations were 1:60, 1:38, and 1:88, respectively.  In contrast, 
animals that received three DNA prime immunizations and were boosted with two 
protein immunization of either matched JR-FL protein or a polyvalent gp120 protein mix, 
achieved geometric mean NAb titers of 1:754 and 1:334, respectively.  The increases in 
potency seen against SF162 when the heterologous DNA prime-protein boost regimen 
was used were statistically higher than those seen with the use of two protein 
immunizations (p=.024), five protein immunizations (p=.028), and the use of five DNA 
immunizations (p=.024). Rabbit sera were next tested against NL4-3, an HIV-1 isolate 
slightly more resistant to neutralization (Fig 2.5B).  Again, consistent with the SF162 
neutralization data, the antibody responses generated through a heterologous 
immunization regimen were significantly more potent than those generated through 
immunization with any single vaccination modality.  Animals that received vector primes 
followed by two protein immunizations were completely incapable of neutralizing this 
virus. This trend only improved slightly in animals that received five protein 
immunizations. Within this group, only serum from a single animal was capable of 
neutralizing the virus, and only at a NAb titer of 1:10.  Rabbits that received five DNA 
immunizations neutralized this isolate with slightly more frequency and potency.  Two of 
the three animals in the group neutralized the virus with a geometric mean NAb titer of 
1:19.  In contrast to the sporadic neutralization seen with the single modality 
immunizations, all six rabbits that received the JR-FL DNA prime and either monovalent 
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or polyvalent protein boost were capable of neutralizing NL4-3.  Geometric mean NAb 
titers of 1:143 and 1:132 were achieved for the two DNA prime-protein boost groups, 
respectively.  This demonstrates another 7-fold increase in potency over the next best 
immune sera from animals that received five DNA immunizations.  Again, the potency of 
neutralization observed when a combination DNA prime-protein boost regimen was 
administered was significantly higher than the potency of neutralization seen when two 
protein (p=0.024) or five protein (p=0.028) immunizations were given. 
Further investigation of this V3-mediated neutralization led us to investigate its 
role in neutralizing the autologous HIV-1 JR-FL isolate.  Initial screening of all sera 
against a JR-FL pseudovirus showed that greater than 50% neutralization was achieved in 
only a single animal in the JR-FL DNA prime-JR-FL protein boost group (Fig 2.6A).  
Previous studies have demonstrated that exposure to soluble CD4 (sCD4) sensitizes 
envelopes to V3-mediated neutralization (120). We utilized this phenomenon to further 
study the functionality of the V3-directed antibodies being generated by each 
immunization regimen.  In these assays, JR-FL pseudovirus was exposed to sCD4 at 5 
µg/mL and sera was then added to the virus to determine if any increases in neutralization 
were observed (Fig 2.6B). This produced even more striking differences in neutralization 
between immunization groups than those observed with SF162 or NL4-3. Against the 
sCD4 exposed homologous JR-FL virus, rabbits that received either two or five JR-FL 
protein immunizations were completely incapable of neutralizing the virus.  Rabbits that 
received five DNA-based immunizations fared better with two of three animals capable 
of neutralizing the virus.  When animals that received the JR-FL DNA prime and 
monovalent protein boost regimen were evaluated, sera from all three animals were  
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Fig 2.6. Ability of serum from rabbits who received JR-FL based immunizations to 
neutralize sCD4 exposed JR-FL.  The functionality of V3-directed antibodies elicited by 
each immunization group was evaluated by their ability to neutralize a sCD4 exposed JR-
FL pseudovirus. A. Neutralization of JR-FL prior to exposure to sCD4. B. Neutralization 
of JR-FL after exposure to sCD4. C. Neutralization of JR-FL after exposure to sCD4 
when sera are preincubated with a matched V3 peptide. Neutralization in the absence of 
sCD4 was calculated according to the following formula: % neutralization = 
[(Preimmune RLUs – Immune RLUs)/(Preimmune RLUs)]*100. When virus was treated 
with sCD4, neutralization was calculated as follows: % neutralization = {[(Preimmune + 
sCD4 RLUs) – (Immune + sCD4 RLUs)]/(Preimmune + sCD4 RLUs)}*100. NAb titer is 
defined as the serum dilution capable of inhibiting 50% of virus infection. Dotted line 
indicates the lowest serum dilution tested. Immunization groups are abbreviated as 
follows: three DNA vector immunizations plus two JR-FL gp120 protein boosts (3V + 
2P), five JR-FL gp120 protein immunizations (5P), five JR-FL gp120 DNA 
immunizations (5D), three JR-FL gp120 DNA immunizations plus two JR-FL gp120 
protein immunizations (3D + 2P), and three JR-FL gp120 DNA immunizations plus two 
polyvalent gp120 protein immunizations (3D + 2pP). 
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capable of neutralizing the sCD4 treated virus.  In rabbits that received the JR-FL DNA 
prime and polyvalent protein boost, two out of three could neutralize the virus.  
Therefore, the inclusion of the DNA prime in the immunization regimen increased the 
quality of the V3-directed antibody response, making it more capable of neutralizing not 
only the V3 sensitive viruses, such as NL4-3, but also the more resistant JR-FL virus 
upon sCD4 treatment.  
Despite evidence that wild type rabbits are not capable of generating antibodies to 
CD4 inducible sites, such as the co-receptor binding site (34), we wanted to confirm that 
the observed neutralization against JR-FL was in fact mediated by recognition of the V3 
loop.  Sera were first incubated with a JR-FL V3-matched peptide 
(CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC) at 25 µg/mL prior to the addition 
to sCD4 exposed JR-FL. As expected, this step eliminated all observed neutralization of 
the JR-FL virus (Fig 2.6C). 
Neutralization of Tier 2 primary HIV-1 isolates 
While we have already demonstrated some differences in the capacity of sera 
from each immunization regimen to neutralize sensitive or Tier 1 isolates, we also wanted 
to determine if there were any differences in the ability of these sera to neutralize other, 
more resistant primary isolates.  To do this we chose to evaluate sera from each 
immunization group against viruses from the standard NIH Tier 2 clade B primary isolate 
panel (56).  While, overall, these viruses are much more resistant to neutralization, we 
observed the superiority of the DNA prime-protein boost approach in eliciting sera 
capable of neutralizing these viruses (Table 2.1).  When only two protein immunizations 
were given, none of the animals elicited a NAb response against any of the Tier 2 viruses.  
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Table 2.1: Neutralization of heterologous primary isolates by sera from rabbits who 
received JR-FL based immunizations. 
617 618 619 620 621 622 626 627 628 623 624 625 629 630 631
6535.3 30 29 29 53 45 31 48 26 47 39 60 67 47 57 59
AC10.0.29 4 23 10 28 33 25 19 6 16 9 6 48 48 55 65
CAAN5342.A2 29 35 37 48 40 36 22 32 42 14 17 59 47 39 74
PVO.4 0 8 0 22 12 22 7 0 16 7 0 37 14 7 36
QH0692.42 24 22 29 25 34 33 39 46 61 24 43 61 25 50 50
REJO4541.67 0 0 25 37 23 29 12 8 30 0 11 35 0 4 24
RHPA4259.7 0 0 12 16 10 6 18 37 51 0 7 36 27 21 27
SC422661.8 10 29 8 33 27 32 21 29 14 17 25 55 44 52 66
THRO4156.18 0 0 0 0 1 0 0 0 0 0 0 22 0 0 28
TRJO4551.58 3 27 33 42 23 26 27 32 41 2 2 29 32 32 51
TRO.11 0 7 31 23 31 40 39 23 26 8 24 32 4 10 25
WITO4160.33 0 1 8 27 0 9 14 2 23 0 0 18 0 0 10
MLV 0 11 1 6 8 0 3 0 15 0 4 14 6 0 13
Numbers indicate % neutralization at a 1:10 serum dilution
3 JR‐FL DNA        
2 5‐Valent Protein
3 Vector           
2 JR‐FL Protein
5 JR‐FL Protein 5 JR‐FL DNA
3 JR‐FL DNA        
2 JR‐FL Protein
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When five protein immunizations were given, neutralization of these Tier 2 viruses was 
also absent with the exception of one animal (Rabbit #620) that was capable of 
neutralizing the 6535.1 isolate. Furthermore, administration of five DNA immunizations 
did not improve neutralization of these viruses; as Rabbits #626 and #627 were not 
capable of neutralizing any of the Tier 2 viruses while Rabbit #628 neutralized two out of 
the 12 isolates (QH0692.42 and RHPA4259.7) at a 1:10 dilution.  The neutralizing 
activity of sera from animals immunized with a DNA prime-protein boost immunization 
regimen improved slightly, but not dramatically. Within this immunization group, one of 
the animals (Rabbit #625) was capable of neutralizing four of the 12 isolates.  However, 
this was not typical as Rabbit #624 could only neutralize one of the 12 isolates and 
Rabbit #626 could not neutralize any. When animals were given the JR-FL DNA prime 
followed by a polyvalent protein boost, the consistency and breadth of neutralization 
were further increased.  The best neutralizer we encountered, Rabbit #631, neutralized six 
isolates (6535.3, AC10.0.29, CAAN5342.A2, QH0692.42, SC422661.8, and THRO4156) 
at a 1:10 dilution.  Rabbit #630 neutralized four isolates in the same panel as Rabbit 
#631.  Rabbit #629 however, could not achieve 50% neutralization against any of the 
viruses tested. The observed neutralization was HIV-1-specific as none of the sera 
neutralized a control Murine Leukemia Virus (MLV) pseudotyped virus (Table 2.1). 
Evaluating the avidity of elicited antibody responses 
Previous studies have suggested that a heterologous DNA prime-protein boost 
approach was able to elicit antibody responses with higher avidity than the homologous 
DNA or protein alone approaches (87, 113). Importantly, recent evidence has indicated 
that antibody avidity may correlate to better protection against SHIV challenge even in 
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the absence of a NAb response in a non-human primate SHIV challenge study (121).  In 
the current study, the avidity of rabbit immune sera being elicited by each immunization 
group was evaluated by measuring how well the serum remained bound to gp120 in the 
presence of increasing concentrations of sodium thiocynate (NaSCN) in an ELISA based 
assay. Evaluating the sera elicited by each regimen in this manner revealed that serum 
avidity differed greatly between different immunization regimens (Fig 2.7). By 
comparing bound IgG from our test animals against an IgG standard, we were able to 
calculate at which concentration of NaSCN 50% of the original bound IgG becomes 
displaced.  Sera from animals who received only two protein injections were most easily 
displaced by NaSCN.  Half of all bound IgG was displaced with an average of a 1.9 M 
solution of NaSCN. When five protein immunizations were given instead of two, 50% of 
IgG remained bound to the plate in a 2.8 M solution of NaSCN. Serum avidity increased 
further with the use of five DNA immunizations. Sera from rabbits that received this 
regimen maintained 50% of IgG binding at a concentration of 3.4 M NaSCN.  The use of 
a DNA prime-protein boost approach improved this further to an average 50% 
displacement at 3.6 and 3.9 M NaSCN for the monovalent and polyvalent gp120 boosted 
groups, respectively. These observed increases in binding avidity with the DNA prime-
protein boost regimen were found to be statistically higher than those seen when only 
protein-based immunizations were used (p = 0.024).  Because only relatively small gains 
in serum avidity were seen with the inclusion of a protein boost, it is likely that the use of 
a DNA immunization induces an initial antibody response with a higher avidity than is 
observed with an initial protein immunization. The increase in binding avidity may be  
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Fig 2.7 Measurement of serum avidity elicited by different JR-FL based immunization 
regimens. Sera were evaluated for their ability to be displaced from autologous JR-FL 
gp120 by increasing molar concentrations of sodium thiocynate (NaSCN).  Dots indicate 
concentration of NaSCN required to displace 50% of bound IgG.  Bars indicate group 
geometric mean. Immunization groups are abbreviated as follows: three DNA vector 
immunizations plus two JR-FL gp120 protein boosts (3V + 2P), five JR-FL gp120 
protein immunizations (5P), five JR-FL gp120 DNA immunizations (5D), three JR-FL 
gp120 DNA immunizations plus two JR-FL gp120 protein immunizations (3D + 2P), and 
three JR-FL gp120 DNA immunizations plus two polyvalent gp120 protein 
immunizations (3D + 2pP). 
3V
 + 
2P 5P 5D
3D
 + 
2P
3D
 + 
2p
P
0
1
2
3
4
5
p=.024
p=.024
[N
aS
C
N
] M
 41
one of the reasons why the DNA prime-protein boost regimen appears to be superior to 
either DNA or protein alone in eliciting a functional antibody response.   
Discussion 
Recent studies have suggested that a heterologous prime-boost vaccination 
approach in which the same antigen is delivered sequentially by different types of 
vaccines is more effective in eliciting humoral immune responses than a homologous 
prime-boost regimen which utilizes only a single vaccine modality (61).  In the current 
study we have built upon previous work (108, 113) in evaluating humoral responses 
generated using HIV-1 gp120 antigen as a model antigen delivered by different prime-
boost regimens.  In this chapter, a rigorous comparison of immunizations was conducted 
with two or five protein vaccinations, five DNA vaccinations, or a combination of DNA 
and protein vaccinations in a rabbit model. We demonstrated that all regimens studied 
were capable of eliciting an equivalent binding antibody response.  However, sera 
generated by each of these immunization regimens proved to differ greatly in more 
important characteristics including specificity, neutralizing activity, and avidity.  This 
finding may have a significant impact on the future development of vaccines. 
Different vaccine delivery approaches have been developed based on the available 
technology at any given time in history.  To date, efficacy and safety have been the final 
parameters driving the development of different vaccine delivery approaches. However, 
little work has been done to compare the detailed parameters of humoral responses 
resulting from these different vaccine delivery approaches. Unfortunately, immune 
correlates of protection are not well understood, even for licensed human vaccines.  
While antibodies are well recognized for playing a major role in protection for many 
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successful vaccines, it is frequently not clear what specific mechanism contributes to 
such protection.  This situation became even more complicated with the discovery of a 
newer generation of vaccination approaches, such as DNA vaccines, viral vector-based 
vaccines, and heterologous prime-boost strategies, because there have been very few 
studies examining how these newer immunization regimens affect the quality of the final 
antibody response. 
Due to the challenge of developing an HIV vaccine, many novel approaches have 
been developed and tested with the goal of raising an optimal antibody response to the 
HIV-1 Env glycoprotein.  The current study utilized some of these novel approaches in 
order to conduct a detailed analysis on the quality of antibody responses elicited by 
different prime-boost vaccination strategies.   
We hypothesized that the measurement of binding antibodies against a protein 
antigen by a polyclonal animal serum may not reflect the difference in detailed antibody 
profiles of such immune sera.  It is well-known that the gp120 form of HIV-1 Env 
protein-based immunizations typically leads to antibodies targeted to the 
immunodominant V3 loop.  We used this region as the first model antigen determinant to 
identify a number of differences among different prime-boost immunization regimens. As 
expected, all immunization regimens used in our study generated antibodies to this 
domain, based upon their ability to outcompeting binding to the V3-directed mAb, 447-
52D.  However, it became apparent that immunization regimens that included a DNA-
based immunization elicited antibodies that were more capable of outcompeting binding 
to 447-52D.  This manifested itself at a functional level in DNA-immunized animals as it 
was observed that these animals were more capable of neutralizing the V3 sensitive 
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isolate, NL4-3.  Similarly, only sera from animals that received a DNA immunization 
demonstrated neutralizing activities against the CD4-sensitized primary isolate, JR-FL. 
Through the use of V3 peptide adsorptions, we further demonstrated that this neutralizing 
activity was mediated by antibodies recognizing the exposed V3 loop after CD4 
treatment. This indicates that the DNA priming step either provides a more relevant 
antigen conformation or generates antibodies with some biophysical quality that is 
superior than those generated through the protein alone vaccination approach.   
Further investigation into epitopes outside of the V3 loop also yielded interesting 
results.  While little to no antibodies targeted to CD4-induced (17b-like) or glycan 
(2G12-like) epitopes were seen through immunization with any regimen, a significant 
number of antibodies capable of outcompeting the CD4bs mAbs, F105 and b12, were 
observed. However, these CD4bs directed antibodies were only seen in animals that had 
received some form of DNA based immunization. Also interesting to note is data 
suggesting that the fine specificities of these antibodies can be shifted with different types 
of protein boosts. Vaccination regimens that included the JR-FL monovalent gp120 
formulation as either DNA alone or in a DNA prime-protein boost format, elicited 
detectable levels of F105 or b12 competition in almost every instance.  However, when 
the JR-FL DNA prime was followed by a polyvalent gp120 protein boost, only a single 
rabbit was capable of outcompeting binding to F105 and b12. This may reveal a shift in 
specificity to CD4 binding sites of subtypes other than clade B, or potentially, but less 
likely, a loss of CD4bs directed antibodies altogether. The fact that antibodies to this 
domain are being generated at all is potentially important based upon evidence that 
broadly neutralizing activity in some individuals is mediated by antibody recognition of 
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this domain (57). This observation makes the use of DNA vaccines a potentially 
attractive platform for HIV vaccine development. 
While using competition assays to dissect antibody specificities revealed 
interesting trends, likely the most relevant comparison is that of the neutralizing activity 
elicited by each regimen. Consistent with previous reports (108, 113), animals that 
received a heterologous DNA prime-protein boost were better capable of neutralizing 
relevant primary isolates. Neutralization of primary isolates was almost completely 
lacking in rabbits that received antigen by only a single vaccine modality. In addition to 
the issue of the method of immunization, and in concurrence with previous data (118), a 
polyvalent formulation of Env antigens appears to play an important role in eliciting a 
broader NAb response than immunization with only a single Env antigen. This may be 
the result of too much focus on a single Env leading to a more potent, but less broadly 
Nab response when only a monovalent formulation is used. 
Additional data demonstrating that immunization with some form of DNA based 
vaccine increases serum avidity to the vaccine antigen is also enlightening. It may be 
possible that the smaller amount of antigen being produced from the initial DNA 
immunizations results in a higher avidity antibody response. This may prove to be an 
important facet of a potential vaccine in light of recent data indicating that serum avidity 
inversely correlates with viral load after challenge (121).  This result points to the need 
for future studies to understand how DNA immunization may affect the generation of B 
cells that produce high avidity antibodies. 
In summary, the studies detailed in this chapter expanded on preliminary findings 
that a combination prime-boost regimen elicits a different profile of antibody responses 
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than immunization with only protein. One interesting point however, is found in the 
comparison between the 5 DNA immunization regimen, and the DNA prime-protein 
boost regimen. Overall, despite similar avidity levels and antibody specificity, as 
measured by competition assay, the 5 DNA immunization group was largely unable to 
neutralize any heterologous primary isolates. This indicates that a protein boost given 
after a DNA immunization may refine the specificity of antibodies originally elicited 
during the DNA priming phase. However, without fine mapping data, this hypothesis is 
difficult to prove. 
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Chapter III 
Unique elicitation of CD4 binding site antibodies by a DNA prime-protein boost 
regimen in rabbits 
Introduction 
In our pre-clinical and clinical immunogenicity studies, we reported that 
polyvalent gp120 formulations, delivered by the DNA prime-protein boost approach, 
elicited NAbs effective against viruses belonging to several different major subtypes of 
HIV-1 (117, 118). In chapter II we began to elucidate the mechanism underlying this 
phenomenon further by identifying unique components of the antibody response that are 
elicited when a DNA component is included in the immunization regimen. We next 
wanted to further this analysis in a preclinical study which laid groundwork for the 
eventual DNA prime-protein boost trial in humans (117).  
Utilizing a polyvalent formulation of gp120s identical to that used in the DNA 
prime-protein boost clinical study (117), NZW rabbits were immunized with either a 
DNA prime-protein boost regimen or a protein alone regimen. The resulting antibody 
responses were evaluated for their fine specificity using peptide mapping and competitive 
binding assays in order to determine if unique regions of gp120 were being recognized by 
sera from animals given a DNA prime-protein boost regimen.  
Results 
Eliciting neutralizing antibodies in rabbit sera using a polyvalent DNA prime-
protein boost Env vaccine formulation DP6-001 
In order to begin to investigate the mechanism behind the broader neutralization 
seen when a DNA prime-protein boost regimen is used, we immunized rabbits with the 
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same 5-valent gp120 vaccine formulation that induced low titer but positive NAbs 
effective against a wide range of primary Env antigens in a recently completed phase I 
clinical study (117).  NZW rabbits were immunized with a 5-valent gp120 formulation in 
either a DNA prime-protein boost or protein alone regimen as described in Figure 3.1. 
Sera collected from rabbits two weeks after the 2nd protein boost in both groups were 
used to evaluate peak level gp120 specific IgG and NAb responses.  By evaluating sera in 
this manner, we determined that the peak level gp120-specific binding titers were very 
similar between the two immunization groups (Fig. 3.2). However, similar binding 
antibody titers did not lead to a similar functional neutralizing antibody response. We 
determined that sera from rabbits that received the polyvalent DNA prime-protein boost 
possessed higher neutralizing activities against a panel of pseudotyped viruses in the 
PhenoSense neutralization system (Table 3.1). Here, we examined three sensitive viruses 
(MN, NL4-3 and SF162) and 12 viruses relatively resistant to neutralization with Env 
antigens derived from primary isolates of clades A, B, C, D, and E. In this assay, only the 
neutralizing activity present at a 1:30 dilution is reported to provide a more stringent 
cutoff for positivity.   All sera, regardless of immunization regimen, neutralized the Tier 
1 sensitive isolates MN, NL4-3, and SF162, at this serum dilution.  In contrast to this, 
only sera from the DNA prime-protein boost group were capable of frequent 
neutralization of the more resistant primary isolates. We determined that the DNA prime-
protein boost group neutralized 8 out of the 12 resistant viruses tested.  Neutralization of 
primary isolates from clades A, C, and D was observed in almost every case in the DNA 
primed rabbit sera.  Three viruses (AC10.0.29, PVO.4 and QH0692.42) from the NIH’s 
Tier 2 clade B standardized panel (56) and JR-CSF (another neutralization resistant  
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Fig 3.1: Immunization groups and 5-valent gp120 vaccine formulation. Rabbits received 
either a DNA prime-protein boost or protein alone immunization regimen. 
Polyvalent
groups Protein alone
DNA prime + 
protein boost
A: 92UG037    B: 92US715    Bal: Ba-L        
C: 96ZM651    E: 93TH976*
gp120 Vaccine
Components*
A, B, Bal, C and E
A, B, Bal, C and E
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Fig 3.2. gp120 specific IgG titers in rabbits immunized with either a DNA prime-protein 
boost regimen or a protein alone regimen against autologous antigens. Data are shown as 
geometric mean titers with bars indicating standard deviation within a group. 
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Table 3.1. Neutralizing antibody responses against a multi-clade panel of HIV isolates 
elicited by polyvalent envelope formulations 
 
Numbers indicate the percent neutralization of indicated virus at a 1:30 serum dilution.  
“–“ indicates less than 50% neutralization at a 1:30 serum dilution. 
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isolate) were not neutralized by any of the rabbit sera (data not shown).  Two rabbit sera 
had neutralizing activity against SC422661.8, from the NIH’s Tier 2 clade B standardized 
panel.  The clade E isolate, 92TH021, was neutralized by only two out of four DNA 
primed sera.  In contrast, sera from rabbits immunized with only protein did not 
neutralize most of the primary viruses. Additional negative controls were also assayed in 
the PhenoSense assay. Rabbit immune sera were tested against Murine Leukemia Virus 
(MLV). Against this irrelevant isolate no neutralization was seen. Additionally, 
preimmune rabbit sera were tested against all HIV isolates in this panel, again no 
neutralization was observed, indicating that all neutralization seen here is HIV specific.   
Epitope mapping of the polyvalent sera using linear overlapping peptides 
To determine differences in antibody specificity between DNA primed versus 
protein alone polyvalent rabbit sera, we first measured serum binding to linear 15-mer 
peptides with an 11 residue overlap derived from the group M consensus gp120 
sequence.  In order to fairly evaluate reactivity irrespective of endpoint titer, all rabbit 
sera were normalized to equivalent gp120 specific binding levels of 200 ng/mL.  Sera 
from both groups had strong reactivity to peptides derived from the C1, C2, V3, and C5 
segments of gp120 (Fig 3.3), including two prominent regions within the V3 loop. Very 
little reactivity was observed against peptides derived from the V1/V2 and V4 loops of 
gp120 for any of the sera tested.   
Interestingly, rabbit sera from the DNA primed group exhibited unique positive 
binding against six regions that were poorly recognized by the protein only sera (see 
arrows in Fig. 3.3).  The size of these six regions vary: peptides 11 (p11) and 30 (p30) 
were recognized as single peptides, peptides 48-49 (p48-p49) and 56-67 (p56-p57) as two  
 52
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.3. Recognition of Consensus M linear overlapping peptides by normalized rabbit 
sera. Sera from rabbits immunized with either a DNA prime-protein boost immunization 
regimen (red curves) or a protein alone immunization regimen (black curves) were 
screened for recognition of overlapping peptides from the gp120 subunit by ELISA. Each 
data point represents average OD values from each animal per immunization regimen. 
Increases in optical density (OD) indicate stronger recognition of the linear peptide. 
Arrows indicate individual or clusters of peptides that were uniquely recognized by 
animals who received a DNA prime-protein boost regimen. 
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adjacent peptides, and peptides 61-64 (p61-p64) and peptides 113-117 (p113-p117) as a 
cluster of several neighboring peptides.  Further analysis of these six highly reactive 
regions indicate that three of them, p30, p61-p64 and p113-p117 contain amino acid 
residues that are part of either the CD4bs or are involved in the binding of the 
neutralizing mAb b12 based on a previously published Env structure (48, 122).  The 
sequences of these peptides are listed in Fig. 3.4.  Average binding to these peptides was 
compared between sera from the two immunized groups.  The DNA prime-protein boost 
group sera had significantly greater recognition of these three regions when compared to 
the protein alone group sera (p < 0.01) (Fig. 3.4).  Overlay of these sequences onto the 
crystal structure of gp120 demonstrates that the locations of these peptides (in blue) are in 
the known CD4 binding region on gp120, overlapping with either previously reported 
CD4 binding residues (Fig. 3.4B, in red) or b12 binding residues (Fig 3.4C, in orange).  
Because a polyvalent Env formulation was used in this rabbit immunization study 
and the sequence differences of these Env proteins, particularly in the variable loops, may 
have precluded recognition of the consensus M peptides, we generated overlapping 
peptides (20mers with 10 aa overlapping) to each of the variable loops from four primary 
gp120 antigens that were used in our study: 92UG037 (clade A), 92US715 (clade B), 
96ZM651 (clade C) and 93TH976 (clade E).  These peptides were then tested for 
antibody recognition with the polyvalent rabbit sera by ELISA (Fig 3.5). Some sequence-
specific variable loop recognition was observed by sera from immunized rabbits against 
peptides derived from the V1/V2 loop of clades A and E Env antigens, in contrast to 
peptides derived from the V1/V2 loop of clades B and C Env antigens.  However, there 
was no differential recognition in this region between the DNA primed 
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Fig 3.4 Additional analysis of three regions of gp120 uniquely recognized by DNA 
primed-protein boosted rabbits. A) Recognition of linear peptides that contain CD4 or 
b12 contact residues by sera from DNA plus protein or protein alone groups by ELISA. 
Data is represented as the mean OD values within a group with error bars denoting 
standard deviation. Sequences of recognized peptides are listed on the right. B) Location 
of the peptides (blue) uniquely recognized by sera from DNA prime-protein boosted 
animals mapped onto the crystal structure of JR-FL gp120 liganded with sCD4 and mAb 
X5. CD4 contact residues are highlighted in red. C) Location of the peptides (blue) 
uniquely recognized by sera from DNA prime-protein boosted animals mapped onto the 
crystal structure of JR-FL gp120 liganded with sCD4 and mAb X5. b12 contact residues 
are highlighted in orange. 
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Fig 3.5. Polyvalent rabbit sera recognition of linear peptides with sequences derived from 
the variable loops of the vaccine antigens. Peptides derived from the variable loops of 
gp120s from clades A, B C, and E were used in graphs A, B, C, and D respectively. Gray 
bars indicate recognition of peptides from sera of DNA prime-protein boosted animals 
while white bars indicate recognition of peptides from sera of protein alone immunized 
animals. The red box corresponds to peptides spanning regions that were also seen to be 
uniquely recognized by DNA primed-protein boosted animals against consensus M 
peptides.  
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 and protein alone groups. Reactivity to the V3 loop was observed for both the DNA  
prime-protein boost and protein alone immunization groups across all gp120 derived 
peptides tested here (Fig. 3.5).  Once again, very little reactivity was generated against 
peptides in V4 region (Fig. 3.5).  For the V5 region, it is striking to find that there are 1-2 
peptides, located at the junction of the V5 and C5 regions, that were recognized by the 
sera elicited with the DNA prime-protein boost approach but not the protein alone sera 
(Fig. 3.5).  Peptides 17 and 18 in Fig. 3.5 correspond to the amino acid sequences 
included in peptides 115 to 117 as shown in Fig. 3.3, and are therefore, in the region 
involved in CD4 binding (96).   
Mapping the specificity of polyvalent sera using virus capture competition 
Competitive virus capture was used to further map antibody specificities. Here, 
polyclonal sera were monitored for their ability to outcompete binding of mAbs with 
known specificity to an HIV pseudovirus. We began by looking at antibodies targeted to 
the immunodominant V3 loop of the HIV Env. Using the V3 specific mAbs 39F and 
LE311 we demonstrated that antibodies with similar V3 directed specificities in the 
polyclonal sera were found in significantly higher titers in animals that received a DNA 
prime (Fig. 3.6). Next, we tested our sera against the glycan specific antibody, 2G12. 
Against this particular mAb, no significant competition was detected in rabbits 
immunized with either immunization regimen. Due to its conserved nature across 
multiple clades, we also tested for the presence of antibodies targeted to the CD4bs. To 
do this we used two antibodies targeted to this domain, the broadly NAb, b12, and the 
narrowly NAb, 15e.  The use of these antibodies as competitive targets revealed that 
higher titers of CD4bs specific antibodies were being elicited in animals that received a  
 57
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.6. Detection of antibody specificities in polyvalent rabbit sera by competition assay. 
Monoclonal antibodies were used to probe the specificities of antibodies present in 
polyclonal sera elicited by a DNA prime-protein boost or protein alone immunization 
regimen. Antibody titer indicates the serum dilution capable of preventing 50% of virus 
binding to a mAb coated plate. % competition was calculated according to the following 
equation: % competition = [(RLUs in absence of sera – RLU in presence of sera)/RLUs 
in absences of sera]*100. White bars indicate group mean titers from sera resulting from 
a DNA prime-protein boost regimen. Gray bars indicate antibody titers from protein 
alone immunized animals. 
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DNA prime compared to those that received only protein. The data described here 
demonstrate that the DNA prime-protein boost approach is more effective in eliciting V3 
and CD4bs antibodies compared to the protein alone approach.  However, these data do 
not prove that these antibodies are responsible for the improved NAb activities observed 
in the DNA primed rabbit sera (Table 3.1).   
To elucidate any potential role of the elevated levels of V3 directed antibodies in 
the neutralization of HIV isolates, we attempted to adsorb the V3-specific antibodies by 
incubating the sera with 15-mer clade B consensus peptides spanning the N-terminal 
strand of the V3 loop (TRPNNNTRKSIHIGPGRAF) as studies have shown this area to 
be the target of several neutralizing V3 mAbs (9, 101-103).  A pilot experiment was 
conducted to confirm that these peptides were capable of adsorbing V3 mediated 
neutralizing activity in rabbit sera by using serum from a control rabbit that was 
immunized with only a V3 peptide fused with a carrier protein (123).  V3 peptide 
adsorption of this serum resulted in a greater than 95% decrease in the neutralizing 
activity against pseudotyped virus expressing Env from HIV-1 isolate SF162, an isolate 
very sensitive to V3 mediated neutralization (Fig 3.7A).  
When sera from the polyvalent DNA prime-protein boost rabbits were first 
incubated with these V3 peptides and then tested for their neutralizing activities against 
pseudotyped virus expressing Env from the HIV-1 isolate SF162, we observed that the  
sera isolated from DNA prime-protein boosted animals were more sensitive to a depletion 
in neutralization (Fig. 3.7B).  Sera from rabbits that received a DNA prime had an 
average of 79% reduction in NAb titers as compared to a 50% reduction in animals that 
received only protein-based immunizations.  The greater sensitivity of the DNA primed  
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Fig 3.7. Effect of V3 peptide adsorption on the neutralizing activity of polyvalent rabbit 
sera against SF162. Clade B consensus V3 peptides were incubated with rabbit sera at 30 
ug/mL prior to exposure to the SF162 pseudotyped virus. Neutralization was calculated 
according to the following formula: % neutralization = [(Preimmune RLUs – Immune 
RLUs)/(Preimmune RLUs)]*100. NAb titer indicates the serum dilution that prevents 
50% of virus infection. A) Effect of peptide adsorption on the neutralizing activity of sera 
from a rabbit that was immunized with only a V3 fusion protein. B) Effect of V3 
adsorption on the neutralizing activity of sera from rabbits who received either a DNA 
plus protein regimen, or a protein alone regimen. Error bars indicate standard deviation 
from replicate experiments.  
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sera to V3 peptide adsorptions supports the previous data that V3-directed antibodies are 
present at higher levels in DNA primed animals.   
We next addressed the role of V3-directed antibodies in the neutralization of more 
resistant primary isolates.  We repeated the V3 peptide adsorptions in an attempt to 
neutralize two clade B primary isolates, SS1196 (Fig. 3.8A) and SC422661.8 (Fig. 3.8B).  
We observed that V3 peptide adsorption had very little effect on the neutralization of 
SS1196 with only an average of a 9% reduction in neutralization.  Against the second 
primary isolate, no reduction in neutralization was observed in the presence of the V3 
peptide.  This indicates that while V3 antibody levels may be elevated in the DNA 
primed animals, they play a minimal role in the neutralization of the more neutralization 
resistant isolates tested here.  This suggests that the increased levels of CD4bs antibodies 
or other unknown conformational antibodies may contribute to the enhanced neutralizing 
activities of the DNA primed sera against more resistant primary viral isolates. 
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Fig 3.8. Effect of V3 peptide adsorption on the neutralizing activity of polyvalent rabbit 
sera against primary HIV-1 isolates. Clade B consensus V3 peptides were incubated with 
rabbit sera at 30 ug/mL prior to exposure to the SF162 pseudotyped virus. Neutralization 
was calculated according to the following formula: % neutralization = [(Preimmune 
RLUs – Immune RLUs)/(Preimmune RLUs)]*100. NAb titer indicates the serum dilution 
that prevents 50% of virus infection. A) Effect of V3 peptide adsorption on neutralization 
of the clade B isolate SS1196. B) Effect of V3 peptide adsorption on the neutralization of 
the clade B isolate SC422661.8. 
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Discussion 
 
  The phenomenon of a DNA prime-protein boost regimen eliciting a broader NAb 
response when compared to immunization with only protein was demonstrated previously 
(109, 118). However, the mechanism underlying the phenomenon was unclear. Our 
previous study implicated the use of a DNA component in the immunization regimen in 
altering the antibody specificity and avidity of the resulting antibody response. In 
particular, we observed an increase in the presence of antibodies capable of outcompeting 
binding to V3 and CD4bs specific mAbs in a competitive binding assay.  
In this study, we confirmed previous data indicating that immunization with a 
DNA prime-protein boost regimen elicits a superior NAb response. Through the use of 
peptide mapping we provide additional evidence that a unique profile of antibody 
responses were being elicited when a combination DNA plus protein regimen was 
administered. We observed a unique pattern of linear epitope recognition in the sera of 
animals that received a DNA prime. These uniquely recognized areas were largely 
focused within the conserved regions of gp120, in particular the C1, C2 and C5 regions. 
Many of these uniquely recognized peptides, in particular the ones derived from the C2 
and C5 regions, contained known contact residues for either sCD4 or the CD4bs directed 
mAb, b12. This peptide binding data was further supported by additional competitive 
binding data which indicated that animals that received a combination DNA plus protein 
regimen produced sera that was more capable of outcompeting binding to V3 and 
CD4bsspecific antibodies. When taken together, these data implicate that the combination 
of DNA and protein immunizations are better able to elicit antibodies to functionally 
conserved domains such as the V3 loop and CD4bs. Because antibodies to the CD4bs 
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have been implicated in broad neutralization in HIV infected individuals (57), it is 
possible that the unique elicitation of antibodies to this domain are responsible for the 
broader neutralization observed when a combination prime-boost immunization is 
administered. Unfortunately, because CD4bs specific antibodies are difficult to 
selectively deplete, we were unable to definitively prove that antibodies with these 
specificities are responsible for the broader neutralization seen when a combination 
immunization is used. Despite this, we were able to demonstrate that the increased levels 
of V3 directed antibodies are likely not entirely responsible for the increased breadth of 
neutralization, as very little neutralizing activity was adsorbed using V3 peptides against 
select clade B isolates. 
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Chapter IV 
Unique elicitation of CD4 binding site antibodies by a DNA prime-protein boost 
regimen in humans 
Introduction 
After establishing in small animals that a different profile of antibody responses 
are being elicited when a combination DNA prime-protein boost regimen was used 
compared to only protein, we next wanted to determine if this effect was also seen in the 
sera of immunized humans. In order to do this, we obtained samples from three different 
HIV vaccine trials. In these trials, healthy human volunteers received one of three 
different immunization regimens. Volunteers from the first of these trials, HVTN 041, 
received a protein alone regimen. Volunteers from the second trial, DP6-001, received a 
DNA prime-protein boost regimen and volunteers from the third trial, HVTN 203, 
received a canarypox prime-protein boost regimen. This trial is of particular interest as it 
was one of the phase II trials leading up the phase III RV144, which showed partial 
protection from HIV acquisition. Using sera from these trials, we evaluated several 
characteristics that could potentially be important in providing protection. The parameters 
that we evaluated include binding titers, neutralizing activity, specificity, ability to 
mediate antibody-dependent cell-mediated cytotoxicity, and activation of the complement 
pathway.  
Results 
All three of the clinical trials included in the current analysis were designed to 
elicit HIV-1 Env-specific antibody responses (Table 4.1).  HVTN 203, was an early 
phase clinical study designed to test the immunogenicity of the canarypox prime-protein  
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Table 4.1: Summary of Vaccine Trials 
Trial 
Prime Immunizations    Boost Immunizations  HIV‐1 
strains 
Adjuvant
Type  Dose  Weeks    Type  Dose  Weeks 
HVTN 
041  
N/A  N/A  N/A 
 
gp120 
protein 
5, 20, 
or 100 
ug 
0, 4, 12  W61D 
AS02A    
(QS‐21 + 
3D‐MPL)
HVTN 
203  
Canarypox 
107.26 
TCID50 
0, 4, 12, 
24   
gp120 
protein 
600 ug  12, 24 
MN, 
GNE8 
Alum 
DP6‐
001 
DNA  1.2 mg  0, 4, 12   
gp120 
protein 
375 ug  20, 28 
A, B, 
Bal,  
C, E * 
QS21 
* A: 92UG037   B: 92US715   Bal: Ba‐L   C:96ZM651   E: 93TH976 
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boost regimen prior to the full scale RV144 efficacy trial in Thailand.  While these two 
studies are similar in the application of the canarypox prime-protein boost concept, they 
differ in the exact antigens delivered to participants in the trial.  HVTN 203 expressed a 
clade B Env by canarypox vector, and was boosted with a bivalent clade B/B Env protein  
formulation from HIV-1 isolates MN and GNE8 (91).  RV144 on the other hand 
expressed a clade E Env by canarypox vector, and was boosted with bivalent clade B/E 
Env proteins, where the two clade E Env antigens in the prime and boost were not 
matched (85).  Volunteers in the HVTN 203 trial received a total of four canarypox 
vector immunizations in addition to protein boosts adjuvanted with alum that were given 
twice and overlapped with the last two canarypox immunizations.   Protein boosts 
consisted of the same recombinant Env protein vaccine that failed to show any protective 
efficacy in a Phase III clinical trial when used alone (33).   HVTN 041 tested the 
immunogenicity of an Env protein derived from the HIV-1 isolate, W61D, without any 
prior immunizations using other forms of vaccines.   A unique feature of HVTN 041 is 
the use of adjuvant, AS02A, a combination of MPL and QS-21 in the oil-in water 
emulsion SB62, to generate strong Env-specific antibody responses in healthy human 
volunteers (37).  The DP6-001 trial used a DNA prime-recombinant protein boost 
immunization approach delivering a 5-valent Env formulation from HIV-1 isolates of 
clades A, B, C, and E (117).  Human volunteers were first immunized three times with 
Env expressing DNA vaccines, followed with two boosts using matched recombinant 
Env proteins in QS-21 adjuvant.  All of the Env proteins used in three studies were in the 
form of gp120. 
Evaluating neutralizing antibody activity elicited by each trial 
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 Neutralizing antibody activity has been a key parameter in HIV vaccine research 
to measure the protective potential of immune sera specific for HIV-1 Env antigens (43, 
100).  Neutralizing antibody activities in sera included in the current report were 
previously tested and showed diverse profiles (37, 91, 117).  Both the HVTN 203 and 
041 trials elicited positive human Env specific antibody responses that were only capable 
of neutralizing T cell line adapted (TCLA) or highly sensitive HIV-1 isolates (37, 91) .   
Data from the HVTN 203 trial indicated that most individuals elicited a serum 
neutralizing antibody response against MN, however, less frequent neutralization toward 
the TCLA strain IIIB was observed.  Serum antibodies from recipients of the HVTN 041 
vaccine were only capable of neutralizing the autologous W61D TCLA strain.  In 
contrast, individuals participating in the DP6-001 trial elicited antibody responses that 
were capable of neutralizing a number of primary isolates from a diverse subset of clades 
(A, B, C, D, and E) albeit at low titers (117).  The main objective of the current study is 
to understand if there is any difference in the quality of these sera that may account for 
the difference of their neutralizing activities.  Because previous neutralizing activity 
analyses for sera from each trial were done in different systems, making direct 
comparisons difficult, a new set of neutralization assays were conducted in the TZM-bl 
assay system. In this analysis, three model HIV-1 primary Env antigens with varying 
degrees of sensitivity to neutralization were used to confirm the previously reported 
neutralizing profiles for these three sets of sera. 
 The vast majority of all sera tested, including 10 of 12 sera (83%) from the HVTN 
203 study, 11 of 12 sera (92%) from the HVTN 041 study, and 20 of 21 samples (95%) 
from the DP6-001 study, were capable of neutralizing SF162, a primary isolate highly 
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sensitive to neutralization (Fig 4.1A).  Geometric mean ID50 titers were 1:62 for the 
HVTN 203 trial sera, 1:164 for the HVTN 041 trial sera, and 1:104 for the DP6-001 trial.  
Statistically, sera from the HVTN 041 trial were significantly more potent neutralizers 
than those from the HVTN 203 study against the sensitive isolate SF162 (p=0.027), but 
not significantly different from DP6-001.   
Neutralizing activities against SS1196, a primary isolate that is moderately 
sensitive to neutralization, allowed for some differentiation of the potential of each trial 
sera (Fig 4.1B).  Only 4 of the 12 sera (33%) from the HVTN 203 trial were capable of 
neutralizing SS1196 at a 1:10 dilution. In contrast, 8 of the 12 sera (67%) from the 
HVTN 041 trial and 18 of the 21 sera (86%) from the DP6-001 trial were capable of 
neutralizing SS1196.  No significant difference in titers were observed among the three 
sets of sera (p=0.09).  However, geometric mean NAb titers for both the HVTN 041 and 
DP6-001 trials were 14 and 13, respectively, much lower than that seen against the highly 
sensitive SF162 isolate.  
 The third pseudotyped virus tested in the current analysis expressed Env from the 
HIV-1 isolate, SC422661.8, a Tier 2 virus representative of those found shortly after the 
establishment of HIV-1 infection in a new patient and known to be highly resistant to 
neutralization (56).  A significant drop in neutralizing activities was observed with sera 
from all three vaccine trials against this virus (Fig 4.1C).  None of the sera from the 
HVTN 203 trial were capable of reaching 50% neutralization at the lowest dilution tested 
(1:10).  Similarly, neutralizing activity against this isolate was only observed in two sera 
(17%) from the HVTN 041 trial.  However, 10 of the 21 sera (48%) from the DP6-001 
trial were capable of neutralizing SC422661.8 at a 1:10 dilution.  The lack of neutralizing  
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Fig 4.1: Confirmation of neutralizing activities against representative HIV isolates.  
Neutralization was calculated according to the following formula: % neutralization = 
[(NHS RLUs – Immune RLUs)/(NHS RLUs)]*100. Neutralizing antibody titers at 50% 
inhibition for each serum are shown against either SF162 (A) or SS1196.1 (B).  
Neutralizing activities against SC422661.8 (C) is shown as the fractions of individual 
sera from each trial either capable of achieving at least 50% inhibition of infection at a 
1:10 serum dilution (shaded portion) or unable to achieve 50% inhibition (open portion).   
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activity from the HVTN 203 and 041 trials against more resistant isolates, and the low 
titer, but broader neutralization seen in the samples from the DP6-001 trial are all 
consistent with previously reported neutralization profiles (37, 91, 117).  It is interesting 
to note that the broader neutralization seen in the DP6-001 samples is present despite the 
fact that, on average, individuals in the DP6-001 had either lower or equivalent titers of 
Env-specific binding antibodies when compared to other two trial sera. 
In order to understand what features of the antibody responses elicited by each of 
these sera may be responsible for the difference in their neutralization profiles, a wide 
spectrum of analyses were conducted to understand the quality of different sera.  The first 
was an evaluation of Env specific binding antibodies.  Because each trial tested here was 
formulated with at least one clade B component, we chose JR-FL gp120 as the model 
detecting antigen to examine binding titers (Fig 4.2).  In addition to being derived from a 
clade B isolate, JR-FL Env antigen is both well characterized and completely 
heterologous to all gp120s included in these studies.  When sera was tested for the ability 
to bind JR-FL gp120, we determined that binding antibody titers generated in the HVTN 
041 trial were significantly higher than those generated in either the HVTN 203 (p=0.04) 
or DP6-001 (p=0.0003) clinical trials, suggesting that gp120 adjuvanted with AS02A is 
an exceptionally immunogenic formulation.  The geometric mean binding titer of the 
HVTN 041 trial was 3.3 fold higher than that of the HVTN 203 trial and 4.5 fold higher 
than that observed for the DP6-001 trial.  The levels of binding antibodies elicited in the 
HVTN 203 and the DP6-001 trials were not statistically different.  
Antibodies directed to CD4 inducible (CD4i) epitopes are frequently elicited in 
HIV infected individuals (26).  However, their role, if any, in controlling viral infection  
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Fig 4.2: Geometric mean endpoint binding titers of sera from each of three human 
vaccine trials against a recombinant gp120 protein of the heterologous clade B JR-FL.  
Error bars indicate standard error. 
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remains unclear.   Prior exposure of pseudovirus to sCD4 can expose CD4i epitopes, such 
as the co-receptor binding site, on the viral envelope (34).  In an attempt to determine if 
sera from any of the HIV vaccine trials being tested in this study elicited CD4i directed 
antibodies, sera from each trial were assayed for their ability to outcompete binding to 
17b, a mAb that targets the co-receptor binding site.  We found that 17b-like antibodies 
were elicited in high frequency and in high titer in all three vaccine trials (Fig 4.3A): 7 of 
12 sera (58%) from the HVTN 203 trial, 9 of 12 sera (75%) from the HVTN 041 trial, 
and 17 of 21 sera (81%) from the DP6-001 trial were able to outcompete binding to 17b 
at a 1:40 serum dilution.  In addition to being elicited frequently, these antibodies were 
all found at relatively high titer, with most sera able to outcompete binding to 17b at 
dilutions in the hundreds.  No statistically significant differences were observed in either 
the frequency or titer of the 17b-competing antibodies elicited among three trials. 
Next, we evaluated if the CD4i antibodies found in the sera from each trial are 
functional in a modified neutralization assay.  Pseudotyped viruses expressing Env from 
the JR-FL isolate were treated with sCD4 prior to incubation with serum in order to 
expose CD4i epitopes, such as the co-receptor binding site, on the viral envelope.  We 
found that while prior sCD4 treatment, JR-FL was difficult to neutralize (Fig. 4.3B), all 
three immunization regimens elicited significant neutralizing activities against JR-FL 
Env pseudotyped viruses upon exposure to sCD4: 7 of 12 (58%) individuals from HVTN 
203, 10 of 12 individuals (83%) from HVTN 041, and 20 of 21 individuals (95%) from 
DP6-001 showed positive neutralizing activities in this assay (Fig 4.3C).  Geometric 
mean neutralizing titers for HVTN 203, HVTN 041, and DP6-001 were 1:28, 1:44 and 
1:49, respectively, without any statistical differences among the three trials.  This data  
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Fig 4.3: Analysis of antibodies against CD4 inducible (CD4i) epitopes.  A) The presence 
of co-receptor binding site-directed antibodies was assayed by competition with the mAb, 
17b.  Competition titer indicates the serum dilution capable of outcompeting 50% of 
pseudoviral binding to 17b. % competition was calculated according to the following 
equation: % competition = [(RLUs in absence of sera – RLU in presence of sera)/RLUs 
in absences of sera]*100. B) Neutralizing antibody titers against HIV-1 JR-FL isolate 
without sCD4 treatment.  C) Neutralizing antibody titers against HIV-1 JR-FL isolate 
with sCD4 treatment.  D) Effect of V3 peptide treatment on neutralizing activity against 
sCD4 treated JR-FL. With no sCD4 treatment % neutralization was calculated according 
to the following formula: % neutralization = [(NHS RLUs – Immune RLUs)/(NHS 
RLUs)]*100. When virus was treated with sCD4 neutralization was calculated as follows: 
% neutralization = {[(NHS + sCD4 RLUs) – (Immune Sera + sCD4 RLUs)]/(NHS + 
sCD4 RLUs)}*100. NAb titer indicates the serum dilution preventing 50% of 
pseudovirus infection. 
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suggests that under the proper conditions, CD4i antibodies present in vaccinee sera would 
be capable of neutralizing heterologous isolates of HIV-1. 
 Because it has been reported previously that sCD4 treatment better exposes the 
V3 loop to antibodies specific for this domain (120), we attempted to determine if the 
neutralizing activity observed after sCD4 treatment was due to recognition of the V3 loop 
or due to recognition of the co-receptor binding site by the 17b-like antibodies detected 
through competition.  To answer this question, vaccinee sera were incubated with a 
synthetic peptide matched to the V3 loop sequence of the JR-FL Env prior to the 
exposure of sCD4-treated JR-FL.  This resulted in a slight drop in the geometric mean 
NAb titer of HVTN 203 sera to 26, of HVTN 041 sera to 25, and of DP6-001 sera to 34 
(Fig 4.3D).  This drop in potency was also accompanied by a drop in the frequency of 
positive neutralizing sera to 6 of 12 individuals (50%) in the HVTN 041 trial and to 16 of 
21 individuals (76%) in the DP6-001 trial (Fig 4.3D).  The observation that a V3 peptide 
was able to block some, but not all of the neutralizing activity indicates that both V3-
directed and co-receptor binding site-directed antibodies may play a role in the 
neutralization of JR-FL after exposure to sCD4. 
In order to further evaluate the presence of antibodies that target other potentially 
neutralizable epitopes without sCD4 treatment, additional competitive binding assays 
were conducted to determine if any of the human immune sera were capable of 
outcompeting binding to known neutralizing mAbs.  Overall, human immune sera 
included in the current study only outcompeted binding to the mAb 2G12 at very low 
frequency. None of the 12 sera from the HVTN 041 trial, 2 of the 12 sera (17%) from the 
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HVTN 203 trial, and 5 of the 21 sera (24%) from DP6-001 trial outcompeted binding to 
2G12 (Fig 4.4A).    
Antibodies capable of outcompeting binding to the neutralizing mAb, 447-52D, 
which is specific for the crown of the V3 loop, were elicited nearly ubiquitously in all of 
the vaccinee sera tested (Fig 4.4B).  The geometric mean competitive binding titers 
against 447-52D were 1:108 for the HVTN 203 sera, 1:409 for the HVTN 041 sera, and 
1:187 for the DP6-001 sera.  Statistically significant differences in the titers of V3-
directed antibodies were observed in the HVTN 041 sera relative to the HVTN 203 sera 
(p=0.008) and the DP6-001 sera (p=0.046). 
 A unique profile of CD4bs directed antibodies was observed upon examination of 
the ability of the immune sera to outcompete binding to the neutralizing mAb, IgG1 b12 
(Fig 4.4C).  Only 4 out of 12 sera (33%) from either the HVTN 203 trial or the HVTN 
041 trial generated an antibody response capable of outcompeting binding to b12.  
However, 20 out of 21 sera (95%) from participants in the DP6-001 trial were capable of  
outcompeting binding to b12 and did so with high titers, sometimes exceeding a 1:500 
dilution.   
The roles of antibodies in a viral infection are not limited to binding and 
neutralization of cell-free virus.  Antibodies can bind to cells coated with HIV-1 Env and 
mediate their killing through an interaction with Fc receptor bearing effector cells.  In 
order to evaluate sera’s ability to mediate antibody-dependent cell-mediated cytotoxicity 
(ADCC), a fluorometric ADCC killing assay was used.  When sera from each trial were 
evaluated in this system, we determined that antibody responses elicited by all three 
immunization regimens were capable of mediating ADCC activity in an equivalent  
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Fig 4.4: Specificity of vaccine-induced antibody responses as determined through mAb 
competition. The ability of serially diluted human immune serum to outcompete binding 
of mAb to a JR-FL & VSV-G pseudotyped virus was measured. % competition was 
calculated according to the following equation: % competition = [(RLUs in absence of 
sera – RLU in presence of sera)/RLUs in absences of sera]*100. Competition titers 
indicate the serum dilution preventing 50% of pseudoviral binding to the mAb.  A) 
Competition with carbohydrate-specific mAb, 2G12. B) Competition with V3 loop-
specific mAb, 447-52D.  C) Competition with CD4bs-specific mAb, b12.
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fashion. Mean lysis of the CEMNKr target cells mediated by sera from each trial was  
 
found to be approximately 20%. (Fig. 4.5).  
A second intrinsic characteristic of antigen specific antibody is the ability to 
mediate activation of the complement pathway.  In order to evaluate human sera’s ability 
to mediate activation of the complement cascade, we conducted an ELISA based assay to 
monitor deposition of C4, a downstream product of complement activation, by gp120 
specific antibody found in vaccinee sera. When this was done, we found that gp120 
specific antibodies from the sera from all three trials were capable of activating the 
complement pathway in a concentration dependent manner. Again however, we observed 
no differences in the abilities of sera from each trial to activate the complement cascade.  
A representative assay result is shown in Fig. 4.6.   
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Fig 4.5: Ability of vaccinee sera to mediate ADCC activity.  CEMNKr target cells were 
pulsed with gp120 prior to exposure of vaccine serum at a 1:100 dilution. Target cell lysis 
indicates the ability of vaccinee serum to mediate cell killing by PBMC from a normal 
human donor as measured by the percentage of CFSE- target cells within the PKH26hi 
population.  Dotted line indicates background cell lysis observed with a normal human 
sera control.  
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Fig 4.6:   The ability of Env specific antibodies to activate the complement cascade 
present in complement intact normal human sera was determined using deposition of C4 
as a marker for complement activation.  A representative plot with data from a single 
individual from each trial is shown.  A) gp120 specific IgG measurement and B) C4 
detection in the same testing sera.  
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Discussion 
 
In the current chapter, a side-by-side comparison was conducted on the quality of 
human antibody responses elicited by three candidate AIDS vaccines focusing on HIV-1 
Env specific antibodies.   Vaccines from all three studies included a gp120 protein 
vaccine component but only two of the studies included priming immunizations using 
either a viral vector- or DNA-based vaccine.  Although the sample sizes are relatively 
small, our results suggest that the antibody profiles elicited by each vaccination regimen 
are different.  This information is valuable for the development of AIDS vaccines with 
potential to elicit protective antibody responses. 
 Volunteers from the HVTN 041 trial had the highest Env specific serum IgG 
titers among the three trials evaluated here.  This was achieved without receiving a 
priming immunization from any gene based vaccine.  Because previous studies using 
recombinant gp120 proteins alone adjuvanted in alum did not generate high binding 
antibodies (33), it is very likely that the strong adjuvant (a mixture of QS-21 and MPL in 
the oil in water emulsion SB62) used as part of the HVTN 041 trial vaccine formulation 
played an important role in the high immunogenicity observed for this recombinant 
gp120 protein vaccine.   A potential caveat to this binding analysis is that the differences 
in binding antibody responses could be due to different degrees of mismatch between the 
vaccine immunogens and JRFL gp120. Even taking this in account however, all three 
trials elicited a significant binding antibody response above 105 against this model 
antigen.    
Consistent with the binding antibody results and the immunodominant nature of 
the V3 loop, competition assays revealed the presence of the highest levels of antibodies 
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specific for the V3 loop among participants in the HVTN 041 trial.  Participants in the 
HVTN 041 trials also showed high neutralizing activities against highly sensitive and 
moderately sensitive pseudoviruses, but poor neutralizing activity against more resistant 
viruses, supporting the hypothesis that recombinant protein-based HIV vaccines are 
highly capable of eliciting antibodies against stable structures that may be masked in 
viruses more resistant to neutralization. 
Sera from the DP6-001 trial, which employed a DNA prime-protein boost 
approach, presented a different antibody profile than that seen in HVTN 041.  This 
regimen was effective in eliciting Env specific binding antibody responses with similar 
characteristics compared to the highly immunogenic HVTN 041 formulation, albeit at a 
slightly lower quantitative level.  Most significantly, however, DP6-001 sera 
demonstrated greater potential to neutralize more resistant HIV-1 isolates, as previously 
reported (117).  Furthermore, sera from the DP6-001 trial exhibited a greater preference 
to elicit antibodies to conformational epitopes, such as the CD4bs, a finding initially 
observed in rabbit immune sera following administration of a similar DNA prime-protein 
boost regimen (108).  While it is difficult to completely attribute the better neutralizing 
activities of the DP6-001 sera to the presence of CD4bs antibodies, conformational 
antibodies such as those specific for the CD4bs and other conformational epitopes have 
been found responsible for the broad neutralizing activities in some HIV infected patients 
(57, 110).   
Sera from HVTN 203 had the least impressive antibody responses in many of the 
parameters measured in the current report.  While the canarypox prime-recombinant Env 
protein boost approach was more effective in eliciting higher binding antibody responses 
 82
than the previous studies using this same Env alone (33), HVTN 203 trial sera were only 
similar to or less effective than the other two trials in eliciting Env-specific antibody 
responses.  Most importantly, HVTN 203 trial sera were less effective than HVTN 041 
trial sera in eliciting binding antibody titers, and less effective than DP6-001 trial sera in 
eliciting antibodies specific for conformationally sensitive epitopes.  Furthermore, HVTN 
203 participants elicited antibodies with the least potent neutralizing activity.  It is not 
clear whether these differences between the canarypox vector prime and the DNA 
vaccine prime can be attributed to the fact that the canarypox vector expresses multiple 
unrelated viral vector proteins in addition to the HIV-1 Env and the DNA vaccine only 
focuses on the expression of Env.    
 Because the same canarypox prime-recombinant Env protein boost approach was 
used in the recent RV144 trial, which showed a low level of protection against HIV-1 for 
the first time in a field trial, the results presented in the current report raise several 
interesting questions.  If a canarypox prime-recombinant Env protein boost approach 
offers any unique protective benefit over the other two approaches, it is then necessary to 
identify new biomarkers other than those included in the current study since none stood 
out as a unique marker for the success of the HVTN 203 trial vaccine.  Alternatively, 
either of the other two approaches evaluated in the current study may have a better 
protective potential over the canarypox prime-recombinant Env protein boost approach if 
the higher responses in binding and neutralizing assays observed in sera obtained from 
only the HVTN 041 or DP6-001 trials are any indication.  However, more advanced 
studies are needed to answer these questions. Interestingly, since each vaccination 
approach has a relatively specific antibody response profile, as discovered in this report, 
 83
it may be possible to link the efficacy of any future vaccine formulation to the antibody 
profile it exhibits.  
 The current report also indicates a great need to expand the scope of research to 
include diverse types of antibody responses when a candidate HIV vaccine is evaluated.  
The presence of NAbs has been used almost exclusively to judge the protective potential 
of vaccine-induced antibody responses.  Our data suggests that other parameters, for 
example, possibly the induction of conformation dependent antibodies, can also provide 
unique insight to differentiate the quality of antibodies elicited by vaccines.  In recent 
studies of HIV infected individuals with broadly neutralizing activity, the neutralizing 
fraction of sera has often been mapped to those antibodies directed towards the CD4bs 
(12, 57, 58, 94).  Because of this, it is exciting to observe the elicitation of antibodies 
with similar specificities as those seen in HIV infected individuals through the use of a 
DNA prime-protein boost regimen.  On the other hand, no differences were observed in 
preliminary analyses of ADCC or complement-mediated antibody effects among three 
sera included in the current study.  
In summary, studies described in this chapter directly compared serum antibody 
responses from three different HIV vaccine clinical trials.  Antibody profiles elicited by 
the three different immunization regimens are similar with regards to the high titer 
binding antibodies that are capable of neutralizing sensitive isolates, mediating killing of 
antigen-coated cells by Fc bearing effector cells, and activating the complement cascade.  
Differences between the vaccine trials became apparent when the neutralizing capabilities 
of sera from each trial were evaluated. We found that participants in the DNA prime-
protein boost trial were capable of neutralizing more resistant primary isolates. In 
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contrast, participants from the canarypox prime-protein boost and the protein alone trials 
demonstrated a much more limited neutralization capacity.  Additionally, profiles of 
antibody specificities differed between the three trials.  We found that participants from 
neither the HVTN 203 nor the HVTN 041 trials were capable of efficiently eliciting 
antibodies directed to the CD4bs of the HIV-1 Env antigen. Because of the unique 
antibody profile and the ability to better neutralize primary isolates, the DNA prime-
protein boost regimen offers another heterolgous prime-boost platform for further HIV 
vaccine development in addition to the recent promising RV144 canarypox prime-protein 
boost regimen.  
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Chapter V 
Mapping the structural basis for antibody responses elicited by DNA prime-protein 
boost vaccines 
Introduction 
After establishing that a combination DNA prime-protein boost regimen is 
capable of eliciting a higher quality antibody response, as defined by the ability to elicit 
antibodies to functionally conserved domains, a higher avidity antibody response, and 
enhanced neutralizing activity against heterologous isolates, we wanted to apply this 
technique to answer a fundamental question in the field of HIV vaccinology: whether or 
not any gp120 immunogen is superior to any other in eliciting a heterologous NAb 
response. The high degree of sequence diversity in the HIV Env results in a protein that 
has a huge diversity of phenotypes. Polymorphisms within Env are responsible for 
changes in structure which can alter viral tropism, antigenicity of Env, and potentially 
even the ability to be transmitted to a new host. However, thus far, no one has been able 
to demonstrate that two naturally occurring isolates differ in their ability to raise a 
heterologous NAb response. In this study, we answer this question with the use of two 
naturally occurring isolates, LN40 and B33.  
Results 
Model envelopes and immunization regimen.  
The LN40 and B33 gp120s were selected for this study due to their high degree of 
sequence similarity but opposing phenotypic properties. A sequence alignment of the  
gp120 subunits from these two Envs are shown in Fig 5.1. To summarize, there are a total 
of 51 amino acid polymorphisms within gp120, which also account for a total of five  
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HXB2    1 MRVKEKYQHL WRWGWRWGTM LLGMLMICSA TEKLWVTVYY GVPVWKEATT  50 
B33       ---------- ---------- ---------- ---....... ..........   
LN40      ---------- ---------- ---------- ---....... .......T..   
 
 
HXB2   51 TLFCASDAKA YDTEVHNVWA THACVPTDPN PQEVVLVNVT ENFNMWKNDM 100 
B33       ........E. .......... .......... ......K... ......R.N.   
LN40      .......... .......... .........S ....P..... .D......N.   
 
 
HXB2  101 VEQMHEDIIS LWDQSLKPCV KLTPLCVSLK CTDLKNDTNT NSSSGRMIME 150 
B33       .......... .......... .......T.N ...FR.A... .......-..  
LN40      .......... .......... .......T.N ....R.A... ....E.K-..  
 
 
HXB2  151 KGEIKNCSFN ISTSIRGKVQ KEYAFFYKLD IIPIDNDTTS YKLTSCNTSV 200 
B33       G......... ..--..D... .......... V...E..... .R.I......  
LN40      E........Y VTPTL.D.K. ....T..... VM...K.N.. .R.I......  
 
 
HXB2  201 ITQACPKVSF EPIPIHYCAP AGFAILKCNN KTFNGTGPCT NVSTVQCTHG 250 
B33       .......I.. .......... .........D .K...K.... ..........  
LN40      .......I.. .......... .........D .K...K.... ..........  
 
 
HXB2  251 IRPVVSTQLL LNGSLAEEEV VIRSVNFTDN AKTIIVQLNT SVEINCTRPN 300 
B33       .K........ .......... ....E...N. ..N......E A......... 
LN40      .K........ .......... ....E...N. .........E .......... 
 
 
HXB2  301 NNTRKRIRIQ RGPGRAFVTI GKI-GNMRQA HCNISRAKWN NTLKQIASKL 349 
B33       .....S.NL- -.....LY.T .E.T.DI... ...L.S...E ....K.VI..  
LN40      .....S.HL- -......Y.T .E.T.DI... ...L.E...E ....K.VI..  
 
 
HXB2  350 REQFGNNKTI IFKQSSGGDP EIVTHSFNCG GEFFYCNSTQ LFNSTWFNST 399 
B33       G....K.... V..P...... ...K...... ......D... ......N---  
LN40      .......... ..N.P..... ...R...... .........K ......N---  
 
 
HXB2  400 WSTEGSNNTE GSDTITLPCR IKQIINMWQK VGKAMYAPPI SGQIRCSSNI 449 
B33       -V.K.L.--. .NG....... .........E .......... ..........  
LN40      -G..RLD..K .NG....... .........E .......... ..........  
 
 
HXB2  450 TGLLLTRDGG NSNNESE--I FRPGGGDMRD NWRSELYKYK VVKIEPLGVA 497 
B33       ...I...... .NKS...PE. .......... .......... ..R.......  
LN40      ...I...... GD..G.KPE. .......... .......... ..........  
 
 
HXB2  498 PTKAKRRVVQ REKR 511 
B33       .......... ....  
LN40      .......... .... 
 
V1/V2 
V3 
V4 
V5 
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Fig 5.1. Sequence alignment of B33 and LN40 gp120s used for DNA immunizations. 
HXB2 gp120 sequence is included as a reference. “.” indicates a sequence identity. “-“ 
indicates a sequence gap. The numbering system used in the alignment, is the standard 
HXB2 numbering system. 
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changes in potential N-linked glycosylation sites (PNGS). These polymorphisms result in 
two Envs with very different phenotypic characteristics (Table 5.1). Briefly, B33 has 
been shown to be highly macrophage tropic, sensitive to neutralization by mAb b12 and 
resistant to neutralization by the mAb 2G12. LN40 however, is not macrophage tropic, is 
resistant to b12, and sensitive to 2G12 (29, 76-78).  
 In order to evaluate their immunogenic potentials, rabbits were primed with either 
B33 gp120 DNA or LN40 gp120 DNA at Weeks 0, 2, and 4. Every animal was then 
given the same 5-valent protein boost, consisting of gp120s from clades A, B, C, and E. 
Half of the animals from each group were boosted on Weeks 8 and 12 while the other 
half were boosted on Weeks 38 and 42 (Fig 5.2). Because all animals received identical 
protein boosts, any differences seen in the resulting antibody responses should be due to 
effects of the initial priming immunizations with either B33 gp120 or LN40 gp120. 
Evaluating binding titers generated through immunization 
Two weeks after the final protein boost, animals were bled and the resulting 
binding antibody response was evaluated against the homologous B33 and LN40 gp120s 
as well as a heterologous clade B gp120, JR-FL. Through these assays, we determined 
that high titer binding antibody responses were generated against both autologous and 
heterologous clade B Envs by priming with either LN40 or B33 gp120 constructs (Fig 
5.3). Against B33 gp120, no differences in the binding titers were observed regardless of 
the priming immunization given (Fig 5.3A). However, a slight difference in binding was 
seen against the LN40 gp120. Sera from animals primed with the LN40 gp120 
recognized the homologous LN40 gp120 protein with approximately a three-fold higher 
titer than animals primed with the heterologous B33 gp120 (Fig 5.3B). Despite this,  
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Table 5.1 Summary of B33 and LN40 Envelope Phenotypes 
Envelope Characteristics
NA420 B33
Highly macrophage tropic, high affinity for CD4, b12 
sensitive, 2G12 resistant
NA420 LN40
Poorly macrophage tropic, low affinity for CD4, b12 
resistant, 2G12 sensitive
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Fig 5.2: Study design and immunization regimen to study B33 and LN40 
immunogenicity. Rabbits received three DNA primes of either LN40 gp120 or B33 
gp120 at Weeks 0, 2, and 4. Protein boosts consisting of a 5-valent mixture of gp120s 
were given as an early boost at Weeks 8 and 12, or as a late boost at Weeks 38 and 42. 
Prime Boost
B33 gp120 DNA
5-Valent rgp120*
LN40 gp120 DNA
*5 Valent rgp20
UG21-9, JR-FL, 92US715, 
MW959, TH14.12
Prime Boost
Week 0 2 4 8 12
Prime Boost
Week 0 2 4 38 42
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Fig 5.3: Endpoint binding titers of sera from rabbits primed with B33 and LN40 gp120s. 
Serially diluted rabbit sera collected 2 weeks after the final protein boost were assayed 
for binding against homologous and heterologous clade B gp120s. A. Endpoint titer 
against B33 gp120. B. Endpoint titer against LN40 gp120. C. Endpoint titer against JR-
FL gp120. Endpoint titer is defined as the last serum dilution giving at least double the 
OD of a preimmune control. 
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endpoint binding titers against the LN40 gp120 still exceeded 105  in both immunization 
groups. Against the completely heterologous JR-FL gp120, no differences in the endpoint 
binding titers were observed between immunization groups (Fig 5.3C).   
 Evaluating neutralizing activity in sera from B33 and LN40 immunized rabbits  
In spite of the observation that immunization with B33 and LN40 generated 
similar, high titer binding antibody responses, we found that the neutralizing activity in 
sera from LN40 primed rabbits was much more broadly reactive (Table 5.2). All animals 
regardless of whether they were primed with B33 or LN40, were capable of neutralizing 
the sensitive isolates SF162 and NL4-3, indicating that a functional NAb response can be 
elicited through priming with both B33 and LN40 gp120s. However, when the ability to 
neutralize more relevant primary isolates is taken into account, only animals primed with 
LN40 gp120 were capable of neutralizing these viruses. Differences in the neutralizing 
activity of sera elicited by each gp120 began to become apparent against the moderately 
sensitive clade B isolate SS1196.1. Three of the four animals primed with LN40 gp120 
were capable of neutralizing this virus at a 1:10 dilution. However, none of the animals 
primed with B33 gp120 were capable of neutralizing this isolate. When evaluating the 
neutralizing activity of the elicited sera against more prototypical primary isolates, 
specifically those tier 2 isolates representative of viruses seen shortly after establishment 
of infection (56), the differences in the neutralizing activity between the two 
immunization groups becomes more dramatic. While the overall breadth and potency 
remains limited, even within the LN40 immunized animals, it is notable that only rabbits 
primed with the LN40 constructs are capable of neutralizing any of the primary isolates 
tested. All four of the LN40 primed animals were capable of achieving 50%  
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Table 5.2: Neutralization of heterologous clade B isolates by sera from LN40 and B33 
primed animals 
Virus 491 652 653 654 492 655 656 657
SF162 96 94 90 89 93 94 89 89
NL4‐3 71 71 98 87 80 72 69 73
SS1196.1 66 56 86 22 28 36 22 37
6535.3 80 57 88 51 29 3 11 73
AC10.0.29 16 19 25 13 20 11 10 13
CAAN5342.A2 54 60 63 49 49 20 42 40
PVO.4 15 15 28 22 23 33 31 23
QH0692.42 52 51 57 19 42 38 13 32
REJO4541.67 6 0 21 6 0 20 12 16
RHPA4259.7 31 53 52 33 23 30 29 29
SC422661.8 24 17 11 9 9 11 9 31
THRO4156.18 24 46 29 35 21 15 7 10
TRJO4551.58 0 19 24 10 10 9 20 9
TRO.11 23 29 32 24 22 0 17 37
WITO4160.33 45 13 0 0 28 0 0 34
MLV 8 4 14 0 0 25 0 5
Numbers indicate percent neutralization at a 1:10 serum dilution
LN40 Primed B33 Primed
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neutralization of the 6535.3 isolate at a 1:10 dilution. Three of the four animals elicited 
an antibody response capable of neutralizing CAAN5342.A2 and QH0692.42 at the same 
dilution. Additionally, half of the LN40 primed animals were capable of neutralizing 
REJO4541.67. In contrast, the only positive neutralization hit we observed in animals 
primed with B33 was against the 6535.3 isolate, where Rabbit #657 achieved greater than 
50% neutralization at a 1:10 dilution. 
To further verify this phenomenon, we purified the rabbit IgG over a protein A 
column and re-evaluated the neutralizing activity against the tier 2 clade B panel (Table 
5.3). These results mirror results seen when only serum was used. Animals primed with 
LN40 gp120 elicited a more potent NAb response than animals primed with B33. In 
some instances, such as seen against neutralization of 6535, LN40 priming resulted in a 
NAb response that was 50 times more potent than the neutralization seen in animals 
primed with B33. While this particular result is exceptional, against the QH0692.42, 
REJO4541.67, and TRJO4551.58 isolates individual rabbit NAb potencies are frequently 
between 2- and 10-fold higher in LN40 primed animals than in B33 primed animals.  
Evaluating the specificity of neutralizing activity using chimeric viruses 
Because the LN40 primed animals appeared to elicit a unique NAb response 
capable of neutralizing a greater breadth of viruses with increased potency, we wanted to 
map the specificity of the observed neutralizing activity. Preliminary neutralization of the 
homologous B33 and LN40 viruses indicated that neutralizing activity elicited by each  
 gp120 was strain specific, with respect to these particular viruses. In every case, sera 
elicited through priming with the LN40 gp120 was capable of neutralizing the  
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Table 5.3: IC50s against heterologous clade B isolates represented as the concentration of 
gp120 specific IgG from LN40 and B33 primed animals. 
Virus 491 652 653 654 492 655 656 657
6535.3 0.63 1.67 0.16 4.30 5.80 3.81 3.48 2.04
AC10.0.29 NA 4.09 6.66 NA NA 4.12 4.30 4.44
CAAN5342.A2 7.57 4.57 5.35 4.04 7.84 4.36 NA NA 10‐5
PVO.4 5.85 2.38 4.70 4.80 7.81 2.64 3.62 3.78 5‐2.5
QH0692.42 1.24 1.10 2.34 4.19 4.13 2.45 3.10 3.73 2.5‐1.25
REJO4541.67 2.64 0.62 0.52 2.62 2.72 1.75 2.51 2.48 1.25‐.625
RHPA4259.7 4.10 4.73 7.41 NA 5.47 NA NA NA .625‐.312
SC422661.8 3.71 3.00 6.47 NA 4.28 NA NA NA
THRO4156.18 2.61 NA NA NA 4.55 NA NA NA
TRJO4551.58 4.27 0.47 0.59 1.55 4.42 3.10 3.39 3.23
TRO.11 3.05 1.38 4.26 2.78 3.62 2.30 1.93 2.42
WITO4160.33 1.24 3.30 3.34 5.20 3.76 4.22 NA NA
MLV NA NA NA NA NA NA NA NA
Numbers indicate IC50 against each virus in ug/mL gp120 specific IgG
NA: 50% neutralization Not Achieved
ug/mL gp120 
specific IgG
LN40 Primed B33 Primed
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homologous LN40 pseudovirus while sera elicited by priming with the B33 gp120 was 
capable of neutralizing the autologous B33 pseudovirus. However, sera from LN40 
primed animals could not neutralize B33 and sera from B33 primed animals could not 
neutralize LN40 (Fig 5.4). This allowed us to further dissect the specificity of the 
neutralizing activity using a series of chimeric viruses.  In total, four chimeric viruses, all 
of which have been previously described (29), were used for this purpose (Fig 5.4A). 
Similar to previous neutralization results with heterologous clade B isolates, none of the 
B33 primed animals achieved 50% neutralization of any of the four chimeric viruses 
tested (Fig 5.4B). The LN40 immunized animals, however, were able to neutralize two of 
the four chimeric viruses tested (Fig 5.4B). The first of these, Stu-B33, contains the C1, 
V1/V2, and N-terminal of C2 of the B33 virus and the remaining C-terminal of the LN40 
virus. At a 1:10 serum dilution, 50% neutralization of this virus was achieved by sera 
from three of the four LN40 primed animals. The fourth animal, while not achieving 50% 
neutralization at a 1:10 dilution, still exhibited a 32% increase in the neutralization 
potency of Stu B33 over the parental B33 virus. The second chimeric virus that was 
sensitive to neutralization by sera from the LN40 primed animals, Stu-Bsu, contains the 
C-terminal portion of C2, the V3 loop, and the N-terminal portion of C3 from the LN40 
gp120. The remainder of the gp120 from this Env is derived from the B33 isolate. Again, 
sera from three of the four animals neutralized this chimeric virus. Similar to what was 
seen with the Stu B33 chimera, the fourth LN40 primed animal, while not achieving 50% 
neutralization, was still more capable of neutralizing this Stu-Bsu chimeric isolate than 
the B33 parent isolate.  
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Fig 5.4: Neutralization of chimeric viruses by rabbits primed with B33 or LN40 gp120. 
A. Schematic of chimeric viruses. White regions indicate Env portions derived from B33. 
Grey regions indicate Env portions derived from LN40. B. Neutralization of chimeric 
viruses. Neutralization was calculated according to the following formula: % 
Neutralization = [(Preimmune RLUs – Immune RLUs)/(Preimmune RLUs)]*100. 
Virus 491 652 653 654 492 655 656 657
B33 5 16 17 14 52 65 56 73
LN40 63 69 67 60 11 10 21 20
Bsu 0 20 15 14 44 8 9 41
Stu LN40 16 0 0 0 13 0 20 19
Stu B33 68 61 64 46 8 21 40 32
Stu Bsu 68 55 54 46 4 20 25 30
Numbers indicate percent neutralization at a 1:10 serum dilution
LN40 Primed B33 Primed
B33
LN40
Stu B33
Bsu
Stu-Bsu
Stu Ln40
V1/V2 V3 V4 V5 gp41
V1/V2 V3 V4 V5 gp41
V3 V4 V5V1/V2 gp41
V1/V2 V3 V4 V5 gp41
V1/V2 V4 V5V3 gp41
V1/V2 V4 V5V3 gp41
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V3 peptide adsorption of sera from LN40 immunized animals   
After narrowing down the region of neutralizing specificity to between the 
sequence spanning the C-terminal of C2 to the N-terminal of C3 from the parental LN40 
Env, we wanted to confirm that the activity we are observing was not simply due to  
recognition of the V3 loop. To account for this possibility we absorbed the immune sera 
with 25 ug/mL of consensus B peptide 
(CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC) prior to the exposure of virus. 
When this V3 adsorption was done against the highly V3 sensitive SF162 isolate, a 
greater than 97% reduction in the NAb titer was observed with sera from all the LN40 
primed animals (Fig 5.5A). However, V3 adsorption had very little effect on the 
neutralization of the fully homologous LN40 virus. In all four cases, less than a 10% 
reduction in neutralization was observed (Fig 5.5B). We then subjected the Stu-Bsu 
chimera to the same analysis. When this was tested, a larger proportion of the 
neutralizing activity was adsorbed with the V3 peptide. Between 14% and 26% reduction 
in neutralization was observed with Rabbits #491, #652, and #653. Only a 4% reduction 
was observed with Rabbit #654 (Fig 5.5C). This bigger drop in neutralization may be due 
to a less efficient masking of the V3 loop by the V1/V2 loop derived from the B33 
isolate. The V1/V2 loop of B33 is both shorter and less highly glycosylated than that of 
the V1/V2 loop from LN40, which may result in V3 being more exposed in the Stu-Bsu 
chimera. Despite the bigger reduction in neutralization with V3 adsorption at this dilution 
step however, the majority of the neutralizing activity directed against this chimera 
remained intact, indicating that not all neutralizing specificity was targeted to the V3 
loop. We also wanted to test one of the primary isolates that was capable of being  
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Fig 5.5.  Effect of V3 adsorption on the neutralizing activity of sera from LN40 primed 
rabbits against homologous and heterologous viruses. Prior to incubation with virus, sera 
was incubated with a clade B consensus V3 peptide at 25ug/mL to determine the role of 
V3 directed antibodies in neutralization activity of sera from LN40 primed animals A. 
Effect of V3 adsorption on the neutralization of SF162. Y axis indicates neutralizing 
antibody titer (ID50). B. Effect of V3 adsorption on homologous LN40. Y axis indicates 
the percent neutralization at a 1:10 dilution. C. Effect of V3 adsorption on chimeric Stu-
Bsu virus. Y axis indicates the percent neutralization at a 1:10 dilution. D. Effect of V3 
adsorption on the neutralization of QH0692at a 1:10 serum dilution. Neutralization was 
calculated according to the following formula: % Neutralization = [(Preimmune RLUs – 
Immune RLUs)/(Preimmune RLUs)]*100. NAb titer indicates the serum dilution 
preventing 50% of pseudoviral infection. 
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neutralized by sera from the LN40 primed animals. To this end, we evaluated the effect 
of V3 adsorption on the neutralizing activity of LN40 primed sera against the QH0692 
isolate (Fig 5.5D). Similar to what was seen with the V3 adsorption of Stu-Bsu we 
observed a slight drop in the capability of our sera to neutralize this virus, however, the 
majority of the neutralizing activity remained intact. This is further evidence that 
neutralizing specificities outside of the V3 loop are responsible for the broader 
neutralization we are observing from sera of LN40 primed animals. 
Identification of residues important for maintaining the neutralizing activity of 
LN40 primed sera  
After eliminating the V3 loop as the likely cause of the broader neutralization 
observed with the LN40 primed sera, we wanted to perform a fine mapping analysis 
using point mutations to determine exactly where the NAbs were targeted. Because we 
already have evidence that the neutralizing specificity is targeted to the Stu-Bsu region of 
Env, we began mutagenesis studies to determine the effects of point mutations within and 
surrounding this region. Interestingly, closer inspection of this region revealed that it 
contained contact residues for CD4 as well as residues that flank the CD4 binding loop at 
the C-terminal end. Additionally, this area had previously been found to confer sensitivity 
to mAb b12 (29). Because of this, we evaluated the effects of mutations in and around 
this region for their effect on neutralization of the parental LN40 virus (Table 5.4). 
 We began by evaluating the effect of a polymorphism found at position 283 
which is known to be part of the CD4bs. The threonine at this position in LN40 was 
mutated to the asparagine found in B33. When this mutation was tested against sera from 
LN40 primed animals, we found that relative to the parental LN40 virus, the LN40N  
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Table 5.4 Point mutations affecting the neutralizing activity of sera from LN40 primed 
animals 
Virus Mutation 491 652 653 654
LN40 71 79 66 66
B33 14 20 14 11
LN40 N T283N 8 17 20 19
B33 T N283T 50 51 21 23
LN40 NL H310N, F317L 58 51 41 22
LN40 K R373K 71 61 52 42
LN40 D N386D 55 71 57 46
LN40 386 ∆Glycan T388V 65 76 59 54
LN40 KD R373K, N386D 21 21 14 0
LN40 KV R373K, T388V 22 27 20 8
LN40 VKPS
I360V, N362K, 
Q363P, P364S
44 64 43 41
Numbers indicate percent neutralization at a 1:10 serum dilution
LN40 Primed
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mutation eliminated almost all neutralizing activity. Interestingly, when the reverse 
mutation was made in the parental B33 isolate, a N283T mutation, the sera from two of 
the LN40 primed animals regained some of the neutralizing activity against this B33T 
mutant relative to parental B33, thus indicating that this position is important for the 
targeting of NAbs in sera from LN40 primed animals. 
 Having some evidence that the neutralizing activity in sera from LN40 primed 
animals was modulated by residues within the CD4bs lead us to evaluate other regions 
known to be important in CD4 and b12 binding. Previous work has implicated two 
residues at positions 373 and 386 in mediating resistance to b12 in the parental LN40 
virus (29). Because of this, we next evaluated the role of residues at these positions in 
modulating the neutralizing activity of sera from LN40 primed rabbits. In the parental 
LN40 virus, we mutated the arginine at position 373 to the lysine that is found in this 
position in B33 to produce the LN40 K mutant. In LN40, at position 386, there is an 
asparagine which is the site of a PNGS. Because of this, we made two mutations that 
would affect this position. The first was to directly eliminate the asparagine at position 
386, and thus the glycosylation, by making an asparagine to aspartic acid mutation to 
create the LN40 D mutant. The second mutant we generated that affects this residue, 
LN40 386∆glycan, eliminates the glycosylation site by mutating the threonine at position 
388 to a valine, thereby leaving the asparagine residue intact but unable to be 
glycosylated due to the elimination of the NxS/T glycosylation signal sequence. When 
we evaluated these mutants for their affect on neutralization we found that all three 
mutants, LN40 K, LN40 D, and LN40 386∆glycan, only resulted in marginal reductions 
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in neutralization compared to the wildtype LN40. In most instances, we observed less 
than a 10% reduction in neutralization against each of these mutants.  
 However, when we made these mutations in combination with each other we saw 
very dramatic effects. When we tested the LN40 KD and LN40 KV mutants, both of 
which affect residues 373 and the glycosylation site at position 386, we saw almost a 
complete loss of neutralizing activity from the sera of LN40 primed animals. These 
residues, which were critical in modulating resistance to b12, also appear to be critical in 
modulating resistance to the antibodies generated through immunization with LN40.  
 As further evidence suggested that antibodies targeted to the CD4bs were the 
cause of the observed neutralizing activity, we wanted to evaluate additional mutations 
that flank the CD4 binding loop. Because this region is highly polymorphic, we made 
four mutations, in concert, in the LN40 backbone. These mutations, an I360V mutation, 
an N362K mutation, a Q363P mutation, and a P364S mutation combined to form the 
LN40VKPS mutant. When tested for its effect on neutralization, these mutations appear 
to play a less critical, but still modulatory role, in the neutralization sensitivity of the 
virus. These mutations, in concert, resulted in an average drop of 22% neutralization 
relative to the parental LN40.   
 Additional mutations were also made in the crown of the V3 loop of LN40 to 
make it identical to that of B33. We determined that these two mutations, H310N and 
F317L, also play a role in modulating sensitivity of the LN40 virus to its autologous sera. 
In this case, we observed a 15-44% drop in neutralization of the LN40 NL mutant relative 
to the parental LN40 virus. Interestingly, this also provides evidence that multiple 
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antibodies targeted to distinct epitopes may act in conjunction to neutralize a single HIV 
isolate.  
Identification of residues important for neutralizing activity of B33 primed sera 
 While we demonstrated that mutations in and surrounding the CD4bs had the 
largest effect on the neutralizing activity of sera from LN40 primed animals, the reason 
for the narrow neutralization seen in sera from B33 primed animals was less clear. 
Historically, antibodies targeted to the V3 loop of the HIV Env have been implicated in 
narrow, type-specific neutralization. For this reason, we began investigating if B33 was 
only being neutralized because of the presence of V3-specific antibodies. To test this, we 
introduced two sets of mutations into the B33 virus. The first set altered the crown of the 
B33 V3 loop to look like that of LN40 by introducing an N310H and a L317F mutation 
to generate the B33 HF mutant. These mutations caused an approximately 20% drop in 
neutralization in two of our sera, and almost no change at all in the other two sera (Table 
5.5).  
 However, two additional polymorphisms between LN40 and B33 that flanked the 
V3 loop also existed. We introduced these mutations, A291S and N310H, in conjunction 
with the N310H and L317F mutations in the B33 backbone to generate the B33 SHFE 
mutant. When we did this, almost all neutralization of the mutant virus was lost against 
the sera from B33 primed animals. This result indicates that the narrow neutralization 
phenotype induced by priming with B33 is likely due to the elicitation type specific V3 
directed NAbs by this particular Env. 
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Table 5.5 Point mutations affecting the neutralizing activity of sera from B33 primed 
animals 
 
Virus Mutation 492 655 656 657
LN40 11 10 21 20
B33 52 65 56 73
B33 HF N310H, L317F 55 42 53 48
B33 SHFE
A291S, N310H, 
L317F, S353E 25 26 19 23
Numbers indicate percent neutralization at a 1:10 serum dilution
B33 Primed
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Discussion 
 In the previous chapters, we established that a DNA prime-protein boost regimen 
elicits a unique profile of antibody responses, which appears capable of eliciting 
antibodies to the CD4bs, and correlates with increased breadth of neutralization. 
Knowing this, we wanted to determine if we could utilize the DNA prime-protein boost 
regimen as a tool to answer another fundamental question of whether or not all HIV 
antigens have equivalent abilities to raise a heterologous NAb response.  
One common criticism of the previously failed phase III Vaxgen trials (33, 80) 
was the use of gp120s only distantly related to those found in circulation. In this set of 
studies, we attempted to determine whether the antigen selection used in a potential 
vaccine is important within the context of generating a binding and neutralizing antibody 
response against HIV. This study utilized two gp120s , LN40 and B33, as model antigens 
to address this question. These two Envs were ideal for this purpose because they were 
isolated from the same individual at the same time point, making them much more 
similar to each other than to any other gp120 from heterologous isolates, while still 
maintaining distinct antigenic phenotypes.  
Dissection of the binding antibody response revealed very little difference 
between the LN40 and B33 gp120s when used in the priming phase of a DNA prime-
protein boost regimen. High titers of cross reactive binding antibodies were seen 
regardless of what gp120 was used as a priming immunization. In contrast to this 
similarity, the quality of the NAb response differed greatly. This result alone warrants re-
evaluation of antibody responses generated in future vaccine trials. No longer should the 
 107
generation of a binding antibody response be considered sufficient for furthering the 
development of a potential vaccine.  
In this study, we demonstrated that LN40, when used as a priming immunization, 
generated a broader heterologous NAb response than priming with the B33 gp120. 
Epitope mapping analysis revealed that the enhanced neutralization observed in the sera 
from LN40 primed animals is likely due recognition of the CD4bs of gp120 (Fig 5.6). 
Again, this data is in agreement with numerous other studies which have indicated that 
recognition of the CD4bs may be a critical domain recognized by sera from HIV infected 
individuals with broadly neutralizing activity (12, 57, 58, 94). To date, however, no 
group has been able to demonstrate that immunization with two different naturally 
occurring gp120s can result in differential elicitation of antibodies to a conserved 
domain. This is especially remarkable given the overall sequence similarity present in the 
LN40 and B33 epitopes. 
In summary, using B33 and LN40 gp120s as model immunogens in a DNA 
prime-protein boost format we have demonstrated that even very similar proteins can 
elicit a different NAb response. This NAb response cannot be predicted solely on the 
presence of binding antibodies against multiple antigens but instead lies in the fine 
specificity of antibodies being elicited by each immunogen.  
Mapping of the neutralizing activity from LN40 primed animals revealed that 
mutations within and surrounding the CD4bs had the greatest detrimental effect on 
neutralization of the autologous LN40 isolate. This evidence suggests that the broader 
neutralizing activity elicited by priming with LN40 may be due to the elicitation of 
CD4bs antibodies. With regards to the highly type specific neutralization seen in sera  
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Fig 5.6. Schematic of amino acid residues important for maintenance of neutralizing 
activity in sera from LN40 primed rabbits. Crystal structure of gp120 liganded with sCD4 
and X5. Yellow highlighted residues indicate the binding footprint of mAb b12. Red 
highlighted positions indicate residues critical for neutralization of LN40 by autologous 
sera. Positions highlighted in blue indicate residues which modulate, but not ablate, 
neutralization of LN40 by autologous sera. Letters indicate the residue found at that 
position in LN40. Numbers indicate the position of that residue according to the HxBc2 
numbering standard. 
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from B33 primed animals, mutations to the V3 loop had the greatest detrimental effect on 
the neutralizing activity of autologous sera. This suggests that the B33 Env may be 
eliciting V3 directed antibodies targeted to an abnormally type specific epitope. These 
findings warrant further investigation of other Env proteins that may further enhance the 
NAb response against HIV isolates or potentially mimic the antibody specificities seen in 
those individuals capable of mediating broad neutralization of HIV. 
 
 110
Chapter VI 
Generation of HIV Specific Monoclonal Antibodies in Rabbits 
Introduction 
Much of our knowledge of the potential of the HIV Env protein as a vaccine 
antigen, in particular its exploitable weaknesses, comes from the study of Env specific 
mAbs. Hundreds of Env specific mAbs have been generated from B cells of HIV infected 
individuals. Of these mAbs, only a handful has been studied in any great detail. This 
subset that has been well studied is largely due to their ability to cross react with or 
neutralize a wide variety of HIV isolates. The most well studied of these antibodies are 
the CD4bs specific antibody, b12, the glycan specific antibody, 2G12, the V3 directed 
antibody, 447-52D, the V2/V3 specific antibodies, PG9 and PG16, and the MPER 
specific antibodies, 2F5 and 4E10.  
To date, the cross reactivity and neutralizing capabilities of these select mAbs are 
the standard by which all other humoral responses are judged. Despite the influence that 
these antibodies have in the HIV vaccine field, there is still an alarming lack of 
information about how well antibodies elicited through immunization compare to these 
well defined mAbs. Part of the reason for this, is that direct comparison of polyclonal 
sera and mAbs is not a fair comparison. For most of these mAbs, the concentration that 
they were present at in the original donors is not known. Therefore, we have no way of 
knowing if the concentrations that these antibodies neutralize at are in fact relevant. 
Additionally, a direct comparison of known mAbs to antibodies generated through 
immunization necessitates the production of monoclonals from immunized animals or 
individuals. Despite the huge number of antibodies generated from infected individuals, 
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very few have been studied from immunized animals. To the best of our knowledge, in 
one of the most useful animal models, NZW rabbits, no HIV specific mAbs have ever 
been isolated.  
All previous analyses in this body of work have studied humoral responses 
elicited through immunization in the context of antibodies present in a polyclonal 
population. However, working with polyclonal sera presents a set of challenges which 
makes definition of the capabilities of a particular subset of antibodies a difficult task. To 
begin, within a polyclonal population the actual number of antibodies targeted to a 
particular epitope and the total number of epitopes being recognized is unknown. As a 
corollary to this, it is theoretically possible that different antibodies specific for the Env 
protein could have interfering or synergistic effects when evaluated in binding or 
neutralization assays. Furthermore defining the epitopes themselves, or capabilities of 
antibodies targeted to a specific epitope, through mutagenic analysis runs the risk of 
inadvertently altering a distal region of the epitope being studied, confounding any 
resulting analysis.   
In this study, we attempt to overcome these challenges and identify the 
capabilities of antibodies elicited through immunization by generating mAbs from a 
single immunized animal. In the current chapter, we report the isolation of thirty-six 
gp120 specific hybridomas from a single DNA primed-protein boosted rabbit. Analysis 
of these antibodies reveals that a wide range of specificities are represented in the 
hybridoma population. These antibodies recognize both linear and conformational 
epitopes and are targeted to multiple distinct regions of gp120. In addition, these 
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antibodies demonstrate different levels of binding cross reactivity as well as 
neutralization of heterologous isolates. 
Results 
Immunization Schedule 
 A single NZW rabbit was immunized using the model clade B gp120 antigen JR-
FL in a modified DNA prime-protein boost schedule in order to examine the 
gp120specific B cell responses at the time of splenocyte isolation (Fig 6.1). Following 
our standard immunization regimen of three DNA primes and two protein boosts, the 
rabbit was given one additional DNA immunization and a final 400 µg protein boost 
delivered intravenously in PBS. Four days after the final protein boost the spleen was 
isolated and shipped to Epitomics for hybridoma production.  
 Defining mAb binding characteristics  
 Screening of cell free supernatants from lines surviving fusion and selection with 
the E240 fusion partner from 4,000 individual wells revealed the generation of 36 gp120  
specific hybridoma lines. Recognition of the autologous JR-FL gp120 by antibody 
secreted from these cell lines are shown by ELISA in Fig 6.2. As demonstrated by the 
data here, all 36 lines secreted antibody that recognized JR-FL gp120 in its native form.  
 Because some of the most highly conserved regions of gp120, such as the CD4bs, 
are conformational in nature, we were also interested in determining if these mAbs 
recognized conformationally sensitive epitopes on the JR-FL Env. To test this, we 
evaluated each mAb for recognition of JR-FL gp120 by Western blot under denaturing 
conditions. This data revealed that antibodies specific for both conformational and linear 
epitopes were being elicited by our DNA prime-protein boost regimen.  We  
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Fig 6.1. Immunization schedule for production of rabbit mAbs. A single NZW rabbit 
received three JR-FL gp120 DNA immunizations by gene gun at Weeks 0, 2, and 4. This 
was followed by two JR-FL protein immunizations delivered intramuscularly in IFA at 
Weeks 8 and 12. A final DNA immunization was given by gene gun at Week 28. The 
final protein boost was given as a 400 µg dose in PBS intravenously at Week 32. The 
spleen was isolated four days after the final protein immunization.  
DNA Protein (50 ug in IFA)
Week 0 2 4 8 12 28 32
Protein 
(400 ug in PBS)DNA
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Fig 6.2 Recognition of JR-FL gp120 by mAbs. Supernatants from hybridoma lines were 
screened for recognition of the autologous antigen JR-FL gp120. Numbers on the X axis 
indicate mAb ID number. “-“ indicates recognition of JR-FL from a polyclonal pre-bleed 
sample at a 1:10,000 dilution. “+” indicates recognition of JR-FL of a polyclonal sera 
sample isolated in week 30 at a 1:10,000 dilution. 
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found that 19 of the isolated antibodies do not recognize linearized JR-FL based upon the 
absence of a JR-FL gp120 band on the Western blot (Fig 6.3). These antibodies were 
identified as mAb numbers, 8, 11, 12, 19, 21, 22, 25, 26, 27, 29, 31, 32, 36, 38, 39, 42, 
47, 52, and 57. The remaining 17 isolated antibodies, mAb numbers, 3, 13, 14, 15, 20, 28, 
34, 35, 40, 41, 43, 45, 50, 51, 53, 55, and 56, recognized the denatured form of JR-FL. 
However, even among these antibodies there was a high degree of variability as to how 
well they recognized the denatured form of the antigen. An example of this occurred with 
mAbs #53 and #55. Antibody #53 recognized the denatured form of JR-FL very 
efficiently, whereas #55 barely recognized it at all. This occurred despite the fact that #55 
recognized JR-FL gp120 by ELISA more efficiently than #53 (Fig 6.3).  
 While identifying the type of epitope being recognized by each antibody is 
valuable, we also wanted to determine if it was possible at this stage to identify individual  
epitopes being targeted by each monoclonal. In order to do this, we utilized the same 
competitive binding assay used in the previous studies. We chose the V3 directed mAb 
3074, the CD4bs directed mAb b12, and the glycan specific antibody 2G12 as 
competitive targets for our monoclonals with unknown specificity. While many of our 
antibodies were not capable of outcompeting binding to any of our known monoclonals, 
we did observe several marginal and two strong competitive hits against 3074, b12, and 
2G12 (Table 6.1).  Of particular interest were the mAbs #52, #53 and #56. Antibody 
numbers 52 and 53 both prevented greater than 50% of viral binding to mAb b12, 
potentially indicating that their binding footprints overlap with that of the CD4bs. 
Antibody number 56, on the other hand, exhibited the strongest competition seen in the 
assay against 3074, providing evidence that it may be targeted to the V3 loop of gp120. 
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 Fig 6.3 mAb recognition of denatured JR-FL gp120. Numbers indicate mAb ID number. 
“+” indicates recognition of denatured JR-FL gp120 by polyclonal sera collected at Week 
30 at a 1:500 dilution. 
3 8 11 12 14 13 15 19 20 21 22 25 26 27 28 29 31 
32 34 35 36 39 38 40 41 42 43 45 47 50 51 52 53 55 
56 57 + 
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Table 6.1 Ability of unknown mAbs to outcompete binding to mAbs of known 
specificity 
mAb 3074 b12 2G12
3 ‐12 22 14
8 ‐17 ‐44 13
11 ‐29 39 ‐1
12 ‐35 46 ‐16
13 2 2 7
14 20 11 17
15 17 24 11
19 17 27 20
20 ‐1 32 22
21 ‐11 26 22
22 1 3 19
25 ‐21 40 18
26 2 8 23
27 20 2 13
28 11 18 10
29 16 44 17
31 37 44 51
32 11 41 39
34 13 30 27
35 ‐6 29 14
36 0 7 22
38 19 33 20
39 22 4 14
40 32 38 17
41 31 45 40
42 8 20 30
43 22 21 28
45 ‐3 4 ‐2
47 ‐8 ‐11 ‐5
50 21 42 27
51 17 ‐2 11
52 27 72 10
53 21 56 39
55 ‐7 28 ‐2
56 83 34 22
57 19 5 6
Competing mAb
 
Numbers indicate % reduction in luciferase activity upon competition with unknown 
mAbs at a 1:2 dilution.
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 The final analysis performed at this stage was to monitor the antibodies’ ability to 
neutralize different HIV isolates (Table 6.2). Unfortunately, due to the low concentration 
of antibodies present in the culture supernatants at this stage, almost always below 1 
µg/mL, very little neutralization was seen. The exceptions to this were seen in 
neutralizing assays with mAbs #28 and #56. Antibody #28 demonstrated marginal 
neutralization against the SS1196 isolate while antibody #56 demonstrated relatively 
potent neutralization against SF162.  
 Based upon the binding and neutralizing data at this stage we selected twelve 
antibodies for further examination. These antibodies, #13, #15, #20, #27, #28, #31, #35, 
#41, #43, #52, #53, and #56, were all subjected to further binding analysis. In an attempt 
to determine the exact specificities of these antibodies, we mapped recognition of linear 
overlapping peptides derived from the clade B consensus sequence.  
Of the twelve antibodies selected for further analysis, four antibodies did not react 
strongly with any of the peptides tested (Fig 6.4). Of these four antibodies, three did not 
react with denatured JR-FL in a Western blot analysis. The fourth antibody, #28, did 
react well with denatured JR-FL gp120 by Western blot but was still negative by peptide 
mapping. This lack of recognition may be due to an epitope that is longer than the 15 
residues encompassed by our peptides, or more likely sequence polymorphisms between 
the peptides and the JR-FL immunogen which could be precluding recognition. If 
sequence polymorphisms between JR-FL and the peptides are in fact precluding 
recognition, it may be possible that mAb #28 is targeted to the Env variable loops, 
however, this is pure conjecture at this stage. 
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Table 6.2 Ability of mAbs to neutralize HIV pseudoviruses 
mAb ID NL4‐3 SS1196 SF162 JR‐FL MLV
3 22 12 17 12 15
8 21 24 25 25 18
11 27 28 21 25 36
12 21 29 25 16 37
13 17 28 24 21 40
14 21 29 25 16 9
15 17 28 24 21 11
19 20 17 13 18 4
20 17 22 ‐1 26 4
21 21 21 9 19 3
22 19 22 17 19 11
25 15 16 17 8 21
26 11 18 22 15 6
27 14 26 29 7 15
28 7 58 39 7 28
29 14 31 8 10 22
31 13 27 12 28 3
32 13 19 ‐4 17 ‐5
34 0 9 ‐3 5 ‐9
35 1 4 13 9 0
36 12 15 19 16 0
38 3 16 2 8 4
39 9 20 13 6 17
40 10 31 ‐8 22 ‐8
41 8 20 ‐21 34 10
42 15 16 8 25 8
43 16 18 ‐8 10 ‐4
45 1 4 ‐29 ‐7 ‐13
47 8 15 6 ‐5 24
50 22 26 17 33 23
51 18 32 20 14 27
52 9 32 11 23 3
53 20 22 14 33 13
55 9 3 ‐21 12 ‐17
56 12 10 88 5 ‐3
57 26 24 11 17 7
Numbers indicate % neutralization of indicated 
pseudovirus by culture supernatants at a 1:2 dilution
Pseudovirus
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Fig 6.4 Monoclonal antibodies with no recognition of consensus B linear peptides A. 
Peptide recognition of polyclonal sera from R662 collected at Week 30 at a 1:1000 
dilution. B. Peptide recognition of mAb #27. C. Peptide recognition of mAb #31. D. 
Peptide recognition of mAb #52. E. Peptide recognition of mAb #28. 
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 Of the remaining eight mAbs tested, three recognized a linear epitope in the C1 
region of Env (Fig 6.5). These three mAbs, #15, #35, and #41, all recognized peptides 
encompassing the sequence TTLFCASDAKAYDTEVHNVWATH. Such similar 
recognition suggests that these three antibodies are either identical or clonally related to 
each other.  
The next grouping of antibodies recognized two distinct epitopes within the V3 
loop of Env. Two of these antibodies, #20 & #43, recognized an epitope on the C-
terminal strand of V3 (Fig 6.6A & B). This epitope encompassed the sequence 
RAFYTTGEIIGDIRQAHCNISRA. Interestingly, these two C-terminal V3 antibodies 
also reacted weakly with a peptide derived from the N-terminal region of C5. This 
peptide spanned the sequence RPGGGDMRDNWRSEL. If confirmed, this may provide 
insight as to the position of the V3 loop in an unliganded gp120 structure.  The remaining 
V3 specific antibody, mAb #56, recognized peptides derived from the N-terminal strand 
and beta turn of the V3 loop. Specifically the mAb recognized peptides spanning the 
sequence TRPNNNTRKSIHIGPGRAF (Fig 6.6D). This sequence specificity correlates 
well with the competition data for this antibody because it strongly outcompeted binding 
to the V3 directed mAb 3074, which has a similar epitope specificity. Additionally, this 
antibody also potently neutralized the isolate SF162, which is known to be highly 
sensitive to V3 mediated neutralization. Furthermore, the N-terminal strand/crown of the 
V3 loop is the target of several neutralizing V3 directed antibodies. Recognition of this 
epitope may explain the relatively potent neutralization of SF162 by this particular mAb 
as well. 
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Fig 6.5 Recognition of consensus B peptides by mAbs with specificity for the C1 region 
of Env A. Peptide recognition of polyclonal sera from R662 collected at Week 30 at a 
1:1000 dilution. B. Peptide recognition of mAb #15. C. Peptide recognition of mAb #35. 
D. Peptide recognition of mAb #41. 
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Fig 6.6 Recognition of consensus B peptides by mAbs with specificity for the V3 loop of 
Env A. Peptide recognition of polyclonal sera from R662 collected at Week 30 at a 
1:1000 dilution. B. Peptide recognition of mAb #20. C. Peptide recognition of mAb #43. 
D. Peptide recognition of mAb #56. 
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The next epitope recognized by a mAb produced in this study was found in the C5 
region of Env. This monoclonal, #13, recognized a set of two peptides from C5 with the 
sequence KYKVVKIEPLGVAPTKAKR (Fig 6.7B).    
The final antibody isolated in this study, #53, is particularly interesting. This 
single antibody appears to recognize peptides from two different regions of gp120 (Fig 
6.8B). The first of these regions is found in the C1 region and spans the sequence 
ATHACVPTDPNPQEV. The second region, found in C4, spans the sequence 
MWQEVGKMYAPPIRGQIRCSSN. This is an interesting collection of peptide 
recognition due to the fact that residues that are recognized in the C4 region are known 
CD4 contact residues. This coupled with the fact that #53 weakly outcompeted binding to 
b12 suggests that this antibody may be targeted to the CD4bs.  
 After identifying regions of gp120 that some of these mAbs are targeted to, we 
next wanted to determine how cross reactive these antibodies are with gp120s from other 
clades. We evaluated this cross reactivity in an ELISA based assay where we monitored 
binding of the mAbs to gp120s derived from clades A (92UG037), B (92US715 & BaL), 
C (96ZM651), and E (93TH976) (Fig 6.9). When this was tested we observed that each 
mAb had a unique pattern of cross reactivity. We first evaluated our antibodies with 
unknown specificity against this panel of gp120s (Fig 6.9A). Of these, mAbs #27, #31, 
and #52 did not cross react with any of the tested gp120s other than the homologous JR-
FL. Antibody #28 fared slightly better with weak cross reactivity with 92US715, 
96ZM651, and 93TH976. We next evaluated the C1 specific mAbs #15, #35, and #41. 
We observed recognition of the clade A and the 92US715 clade B gp120 by mAbs #35  
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Fig 6.7 Recognition of consensus B peptides by mAbs with specificity for the C5 region 
of Env A. Peptide recognition of polyclonal sera from R662 collected at Week 30 at a 
1:1000 dilution. B. Peptide recognition of mAb #13.  
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Fig 6.8 Recognition of consensus B peptides by mAbs with specificity for multiple 
regions of Env A. Peptide recognition of polyclonal sera from R662 collected at Week 30 
at a 1:1000 dilution. B. Peptide recognition of mAb #53.  
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Fig 6.9. Cross reactivity of mAbs to gp120s of different clades. Hybridoma supernatants 
were screened for recognition of gp120s derived from isolates from clade A 
(92UG037.8), clade B (92US715, BaL, & JR-FL), clade C (96ZM651), and clade E 
(93TH976.17). “R662” indicates recognition of the various gp120s by polyclonal sera 
from the parental rabbit at a 1:1000 dilution. A. Recognition of gp120s by conformational 
or unknown antibody specificities B. Recognition of gp120s by C1 specific antibodies C. 
Recognition of gp120s by V3 specific antibodies D. Recognition of gp120s by a C5 
specific antibody (#13) or a C1/C4 specific antibody (#53)  
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and #41. However, no recognition of the clade C or clade E gp120 in this study was seen. 
Recognition of this multiclade panel by mAb #15 was similar to that of #35 and #41, with 
the exception that mAb #15 also recognized the clade C gp120.  
The V3 directed antibodies were also tested for recognition of this panel of 
gp120s (Fig 6.9C). Monoclonals #20 and #43, the two C-terminal strand V3 specific 
antibodies, were able to weakly cross react with all the gp120s in this panel except for the 
clade E gp120.  The V3 directed antibody specific for the N-terminal strand, #56, 
demonstrated the broadest cross reactivity of all the mAbs tested in this study. This mAb 
was able to recognize every single gp120 it was tested against.  
Finally, we tested the C5 specific mAb #13 and the C1/C4 specific mAb #53 (Fig 
6.9D). We found that mAb #13 recognized 5 out of the 6 gp120s it was tested against. 
The one exception to this was the lack of reactivity to the clade C gp120.  When mAb 
#53 was tested against these gp120s, we determined that it is as cross reactive as the V3 
mAb #56. Monoclonal #53 was capable of recognizing all six of the gp120s in this panel.    
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Discussion 
 
The type of mutagenic analysis used in the previous chapter is an extremely 
valuable means by which to dissect the neutralizing activity and specificity of polyclonal 
sera. However, due to the diverse number of epitopes being targeted by antibodies in 
polyclonal sera it is difficult to define exact antibody specificities and activities. This 
difficulty stems from the risk of one mutation having global effects on the target Env and 
affecting a region distal to the experimental mutation. Because we wanted to study the 
capabilities of individual antibodies generated with our DNA prime-protein boost 
approach, we generated mAbs from a single DNA primed-protein boosted rabbit. This 
allowed us to directly compare capabilities of antibodies elicited through immunization to 
those broadly NAbs that were elicited through natural infection. 
After hybridoma fusion and selection, we identified 36 lines which all secreted 
antibody that recognized the autologous JR-FL gp120. Initial characterization of these 
lines revealed that antibodies recognizing both linear and conformational epitopes were 
being represented approximately equally. Additionally, some of these antibodies 
demonstrated the capability to neutralize heterologous virus and outcompete binding to 
known neutralizing mAbs.  
After this initial screening, we selected 12 antibodies for further testing. 
Additional epitope mapping revealed that antibodies recognizing linear epitopes were 
found to target the C1, V3, C4, and C5 regions of Env. When we tested these antibodies 
for binding cross reactivity against multiple gp120s from different clades, we observed a 
highly variable pattern of cross reactivity. While some of these antibodies, such as #27, 
#31, and #52, only react with the autologous JR-FL gp120, others, such as #53 and #56, 
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cross react with every gp120 they have been tested against. This data suggests that some 
of the antibodies being elicited through this vaccination regimen have greater abilities to 
cross react with heterologous gp120s than sera from some HIV infected individuals 
(117). Additionally, we provide evidence that these antibodies are targeted to functionally 
important domains, such as the CD4bs and the V3 loop. Also, some of these antibodies 
are capable of mediating neutralization of heterologous HIV isolates.  
In this study, we have proven that it is viable to generate mAbs from DNA 
primed-protein boosted rabbits. From the antibodies that were generated, we were able to 
demonstrate that immunization with gp120 elicits antibodies to both linear and 
conformational epitopes, that these antibodies have diverse specificities for different 
regions of gp120, and these antibodies vary in their cross reactivity to Envs of different 
clades. Importantly, mAbs that were generated appear to be targeted to functionally 
important regions such as the CD4bs and the V3 loop. While thus far, only limited 
neutralization has been performed, these assays are ongoing. We hope to demonstrate that 
mAbs generated through this immunization approach have the capability to neutralize 
diverse isolates of HIV. 
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Chapter VII  
Materials and Methods 
HIV-1 gp120 DNA vaccines 
All constructs used for DNA immunizations were HIV-1 gp120s cloned into the 
pJW4303 vector, as previously reported (113).  DNA was produced in HB101 bacterial 
cells then isolated and purified using the Qiagen Plasmid Maxi or Mega Kits. Env gp120 
constructs derived from the JR-FL, 92UG037, 92US715, Ba-L, 96ZM651, & 93TH976 
were all codon optimized. Env gp120s from LN40 and B33 were of wild type codon 
usage.   
 HIV-1 gp120 protein vaccines 
Recombinant HIV-1 gp120 proteins were produced from Chinese Hamster Ovary 
(CHO) cells.  The JR-FL gp120 protein was produced by Progenics and provided by Dr. 
John Warren at Division of AIDS, NIAID, NIH. The gp120s derived from 92UG037.8, 
Ba-L, 96ZM651, and 93TH976.17 were produced in CHO cells at Advanced BioScience 
Laboratories. Other gp120 Env glycoproteins from subtypes A (UG21-9), B (92US715), 
C (MW959), and E (TH14.12) were all produced by Dr. James Arthos.  Secreted proteins 
from stably transfected CHO cell lines were harvested and purified over a lectin affinity 
column. 
Antibodies 
The CD4bs directed mAbs, b12 and b6 were obtained as a gift from Dr. Dennis 
Burton or purchased from Polymun. The V3-directed mAb, 447-52D and 3074, were 
provided as a gift from Dr. Susan Zolla-Pazner.  The co-receptor binding site antibody 
17b and the V3 directed antibodies 39F and LE311 were provided by James Robinson. 
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The mAbs 2G12, and F105 were obtained through the NIH AIDS Research & Reference 
Reagent Program.  
Rabbit Immunizations  
NZW rabbits at 6-8 weeks of age were purchased from Millbrook Farm (Amherst, 
MA) and housed in the animal facility managed by the Department of Animal Medicine 
at the University of Massachusetts Medical School (UMMS) in accordance of the 
protocol approved by UMMS’ Institutional Animal Care and Use Committee (IACUC).  
When DNA immunizations were given, DNA encoding the appropriate 
immunogen or the pJW4303 vector control were coated onto 1 micron gold beads at a 
ratio of 2 µg of DNA per milligram of gold beads and delivered to animals via a Bio-Rad 
Helios gene gun onto shaved abdominal skin.  Each animal received 36 µg of DNA per 
immunization. Where appropriate, protein immunizations were administered consisting 
of either 50 µg of a single gp120 protein or 10 µg each of a 5-valent formulation of 
gp120s.   Prior to injection, 50 µg of gp120 protein was diluted in 500 µL PBS and mixed 
with 500 µL IFA. The 1 mL adjuvanted protein solution was then injected 
intramuscularly into the lumbar region of rabbits.  Serum was collected for antibody 
studies two weeks prior to the first immunization and two weeks after each animal 
immunization.  
Endpoint Binding ELISA 
All coating antigens with the exception of LN40 and B33 gp120 used in Chapter 
VI were purified gp120s identical to those used for the immunization of rabbits. In 
chapter VI, LN40 and B33 antigen used for coating plates was produced by transient 
transfection of 293T cells. Recombinant gp120 protein was coated onto 96 well 
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microtiter plates (Costar) at 1 µg/mL in 100 µL of PBS for 1 hr at room temperature. 
When LN40 and B33 protein was coated on ELISA plates, 100 µL of serum free cell 
culture supernatants was used. Plates were then washed 5 times in PBS containing 0.1% 
Triton-X (EWB) and blocked overnight at 4°C in PBS containing 4% whey by weight 
(whey dilution buffer) and 5% powdered milk. The following morning, plates were 
washed 5 times in EWB and serially diluted rabbit sera, collected at 2 weeks following 
the final protein immunization, was added to the wells in a volume of 100 µL. Plates 
were washed 5 times in EWB and 100 µL of biotinylated anti-rabbit secondary antibody 
(Vector Labs) at 1.5 µg/mL was incubated on the plate for 1 hr at room temperature.  
Plates were washed 5 times with EWB and incubated with 100 µL of a streptavidin 
horseradish peroxidase construct (Vector Labs) at 500 ng/mL. Plates were washed 5 
times with EWB and developed for 3 min in 100 µL of a 3,3’5,5’-tetramethylbenzidine 
substrate solution (Sigma). The reaction was stopped with addition of 25 µL of 2N 
H2SO4. Endpoint titers as reported are defined as the last dilution of a serially diluted 
serum sample with greater than double the background optical density of a preimmune 
serum sample. 
Peptide Binding ELISA 
Microtiter plates (96 wells) were coated with 100 μl of individual overlapping 15 
mer peptides (4 μg/ml) derived from the consensus HIV-1 M group gp120 sequence, 
obtained from the NIH HIV Research and Reference Reagent program.  Plates were 
incubated at room temperature for 1 hour, then washed 5 times with 200 μl wash buffer 
(0.1% Triton-X in PBS) and blocked overnight in 4% whey dilution buffer containing 1% 
by weight powdered milk.  Plates were washed again and incubated with 100 μl rabbit 
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sera normalized to 200 ng/ml gp120-specific IgG for 1 hour at room temperature.  Plates 
were washed again and incubated with 100 μl of 1 μg/ml biotinylated anti-rabbit Ab (BA-
1000, Vector Labs) for 1 hour at room temperature.  After additional washes, 100 μl of 
500 ng/ml HRP conjugated streptavidin (Vector Labs) was added for 1 hour at room 
temperature.  Plates were washed 5 times with EWB and developed for 3 min in 100 µL 
of a 3,3’5,5’-tetramethylbenzidine substrate solution (Sigma).  The reaction was stopped 
by the addition of 25 μl 2N H2SO4.  Plates were then read using a Dynex® OpSys MR 
plate reader.  
In chapter III, the polyclonal rabbit sera were normalized using a semi-
quantitative ELISA to determine the concentration of gp120-specific IgG in each.  The 
gp120 used to coat plates was the matched 5-valent mixture (1 μg/mL of each 
component).  The concentration of gp120-specific IgG in each serum was determined 
against a standard curve generated using a known rabbit IgG (Southern Biotechnology 
Associates), as previously described (116).  Rabbit sera were prepared to normalized 
concentrations of 200 ng/mL of gp120-specific IgG for screening of overlapping 
peptides.  In chapter V, the concentration of gp120 specific purified IgG was calculated 
in a similar fashion. 
HIV-1 Neutralization Assays 
Neutralization assays reported here were done in one of two ways. In most assays 
neutralization was performed using the TZM-bl reporter cell line as previously described 
(67).  In some indicated cases, the Phenosense neutralization system was utilized by 
Monogram Biosciences (86). 
Phenosense Neutraliation Assay  
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The PhenoSense neutralization assay was conducted through a subcontract using 
the PhenoSense Assay system at Monogram Biosciences.  In this system, pseudovirus 
was harvested 48 hours after co-transfection of HEK293 cells with pCXAS-Env libraries 
plus an HIV genomic vector that contains a firefly luciferase indicator gene.  
Pseudoviruses were the incubated for 1 hour at 37°C with heat-inactivated rabbit sera at 
graded dilutions.  U87 cells expressing CD4 and the CCR5 and CXCR4 co-receptors 
were inoculated with virus-Ab mixtures in the absence of added cations.  Virus infectivity 
was determined 72 hours post-inoculation by measuring the amount of luciferase activity 
expressed in infected cells.  Neutralizing activity was calculated as the percent inhibition 
of viral replication (luciferase activity) at each antibody dilution compared with a rabbit 
serum free control: % inhibition = [1 − (luciferase + immune sera)/(luciferase − immune 
sera)] × 100.  Pre-bleed rabbit sera were also included as negative controls.  MuLV was 
also included in each assay to rule out non-specific neutralizing activities. 
TZM-bl Neutralization Assay. 
  HIV-1 pseudovirions were produced through cotransfection of the pSG3Δenv 
backbone (NIH AIDS Research Reference and Reagent Program) and an Env gp160 
bearing plasmid in HEK 293T cells.  Pseudovirus containing supernatants were cleared of 
cell debris by low speed centrifugation.  Pseudoviruses were then titered out on the TZM-
bl cell line before use.  For a typical neutralization assay, 200 TCID50 of pseudovirus was 
incubated with rabbit sera for 1 hr at 37°C.  The pseudovirus/sera mix was then added to 
104 TZM-bl cells in a final concentration of 20 µg/mL DEAE Dextran. Plates were 
incubated at 37°C for 48 hours and developed with luciferase assay reagent according to 
the manufacturer’s instruction (Promega). Neutralization was calculated as the percent 
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change in luciferase activity in the presence of preimmune sera versus that of luciferase 
activity in the presence of immune sera [(Preimmune RLUs – Immune 
RLUs)/(Preimmune RLUs)]*100. 
In peptide adsorption experiments the same neutralization protocol was applied as 
described above except, prior to the exposure of sera to the pseudovirus, the sera were 
incubated with an equal volume of a V3 peptide at 25-30 µg/mL for 30 minutes at 37°C.  
Additionally, in some assays, pseudovirus was exposed to sCD4 prior to the 
addition of sera. In these assays, JR-FL pseudovirus was preincubated with 5 µg/mL 
sCD4 (NIH AIDS Research and Reference Reagent Program) prior to the addition of 
serum.  In these assays, percent neutralization was calculated with the light signal of JR-
FL in the presence of sCD4 serving as our baseline light signal. 
Competitive Binding Assays 
Competitive binding assays were performed as previously described (25, 28) with 
minor modifications.  Pseudovirions bearing the JR-FL Env and Vesicular Stomatitis 
Virus (VSV) glycoprotein were produced with the pSG3ΔEnv backbone in 293T cells. 
Microtiter plates were coated with 50 µL of mAb at 5 µg/mL for 1 hr at room 
temperature. Plates were then blocked in PBS with 3% BSA overnight at 4°C.  Rabbit 
sera was heat inactivated at 56°C for 30 min, serially diluted, and incubated with 
pseudovirus correlating to 2.5 ng of p24/well for 1 hr prior to the addition to the 
virus/sera mixture to the ELISA wells. Pseudovirus/sera mixture was then incubated on 
the ELISA wells for 3 hrs at room temperature. Plates were washed 5 times with sterile 
PBS and overlayed with 10,000 TZM-bl cells per well. Plates were then incubated for 48 
hrs at 37°C. Luciferase activity was determined per the manufacturer’s instruction 
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(Promega). Competition titer is reported as the serum dilution at which the luciferase 
signal is reduced by 50% compared to a serum negative control. When competition with 
the co-receptor binding site antibody 17b was tested, the pseudovirus was incubated with 
sCD4 at 5 µg/mL for 30 min at 37°C prior to the exposure of sera. 
NaSCN Displacement  
JR-FL gp120 was coated onto 96 well microtiter plates (Costar) at 1 µg/mL in 
100 µL of PBS for 1 hr at room temperature. Plates were then washed 5 times in PBS 
containing 0.1% Triton-X (EWB) and blocked overnight at 4°C in PBS containing 4% by 
weight whey (whey dilution buffer) and 5% powdered milk. Rabbit sera were then added 
to the plate at either a 1:30,000 or 1:100,000 dilution and incubated at room temperature 
for 1 hr. Plates were then washed 5 times in EWB. NaSCN was then added at various (0, 
1, 2, 3, 4, 5 M) concentrations in PBS for 15 min followed by 5 washes in EWB. Bound 
IgG was detected as described above. Determination of IgG quantity remaining on the 
plates was done using linear regression analysis of a standard IgG curve (Southern 
Biotech). Data is reported as the NaSCN concentration required to displace 50% of IgG 
initially bound on the plate. 
Antibody Dependent Cell mediated Cytoxicity (ADCC) 
The ability of serum from immunized individuals to mediate ADCC activity was 
performed as previously described with minor modifications (38). Briefly 1 x 106 
CEMNKr cells were dual stained with 2.5 x 10-6 M PKH-26 (Sigma) and 5 x 10-8 M 
CFSE (Molecular Probes, Invitrogen). Cells were then washed in PBS and incubated with 
5 µg of JR-FL gp120 for 1 hr at 25°C. Following another wash in PBS, CEMNKr cells 
were plated at 5000 cells/well in 50 µL RPMI with 10% FBS in a 96 well tissue culture 
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dish. 100 µL of sera diluted in RPMI with 10% FBS were then added to the cells at a 
final dilution of 1:100. After a 15 minute incubation, 50 µL of effector cells were added 
to the plate at a 50:1 E:T ratio. Plates were centrifuged at 400g for 3 min to promote cell-
cell contact and then incubated at 37°C for 4 hours. Following the 4 hour incubation, 
cells were subjected to flow cytometric analysis on a LSRII cytometer for loss of CFSE 
fluorescence within the PKH-26hi target cell population. Cell lysis is defined as the 
percentage of CEMNKr cells in the PKH-26hi population that lost CFSE fluorescence. 
Negative controls included normal human serum as well as CEMNKr cells that were not 
pulsed with gp120. 
Detection of complement activation 
 The downstream product of complement activation, C4, was detected in an 
ELISA based assay. 50 uL of JR-FL gp120 was coated on a microtiter plate at 1 µg/mL 
overnight at 4°C. Plates were then washed five times in PBS with .025% Tween-20 
(EWB). Plates were blocked in 200 µL of PBS containing .025% Tween-20 and 3% 
BSA. After washing, serial dilutions of human sera that had been heat inactivated for 30 
min at 56°C was then added to the gp120 coated plate and incubated for 1 hr at room 
temperature (RT). After washing, intact normal human sera was incubated on the plate at 
a 1:100 dilution for 1 hr at RT. Plates were then washed and a goat anti-C4 antibody 
(Immunology Consultants Laboratories) was added to the plate at a 1:1000 dilution for 1 
hr at RT. After washing an AP conjugated anti-goat secondary was added to the plate at a 
1:1000 dilution and incubated for 1 hour at RT. After washing the plate was then 
developed with 50 µL of AP development solution consisting of diethanol amine buffer 
plus phosphatase substrate (Sigma). 
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Site Directed Mutagenesis  
All site directed mutagenesis was perform using the Stratagene Quikchange II site 
directed mutagenesis kit according to the manufacturers instructions. Mutagenesis was 
verified by sequencing the gp120 Env. 
Production of rabbit hybribdoma lines 
Rabbit hybridoma lines were produced as previously described by contract with 
Epitomics (99). Briefly, splenocytes harvested from immunized rabbits were fused with 
the 240E 1-1-2 fusion partner at a ratio of 2:1 with 50% PEG 4000 at 37°C in serum free 
media. Cells were then plated out in microtiter plates in culture media with 15% FBS. 
After 72 hours, HAT was added and media was changed every 5 days. Wells containing 
antigen specific cell lines were screened by testing cell free culture supernatant for 
recognition of JR-FL gp120 antigen by ELISA. 
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Chapter VIII 
Final Comments and Conclusions 
The primary goal of the HIV vaccine field is to develop a vaccine that is able to 
elicit an immune response capable of providing protection from viral acquisition. 
Unfortunately, there is still no known natural correlate of protection from HIV infection. 
To date, the only means of providing sterilizing immunity in an experimental system is 
the passive transfer of NAbs (24, 31, 45-47, 64, 66). This evidence makes it a strong 
likelihood that any successful vaccine will require a strong, high quality antibody 
response as an essential component.  
A large portion of our knowledge of HIV specific antibody responses comes from 
the study of HIV infected individuals, especially those whose sera possess broadly 
neutralizing activity. Through examination of these individuals’ sera or mAbs produced 
from these patients, we have identified numerous weaknesses in the viral Env protein that 
can be exploited by the host antibody response to prevent viral infection. These regions 
include the CD4bs, the V3 loop, unique patterns of glycosylation, the coreceptor binding 
site, conformational epitopes involving the V2 and V3 loops, and the MPER region of 
gp41. While the field is beginning to gain an understanding of how the host antibody 
response evolves in an attempt to counter the virus, data is still sorely lacking on the 
extent of our capabilities to mimic this response by exploiting viral weaknesses through 
vaccination. In the work presented in this dissertation, I attempted to address this gap in 
knowledge by using one of the few tools available that has been shown to induce a high 
quality NAb response to HIV, a heterologous prime-boost regimen consisting of a DNA 
prime followed by protein boosting.  
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In this body of work we have studied the humoral responses elicited by the DNA 
prime-protein boost immunization regimen. Using this as a baseline, we have compared 
antibody responses elicited by DNA alone and protein alone regimens in small animals 
and protein alone and canarypox prime-protein boost regimens in humans. Based on 
these comparisons, we determined that a DNA prime-protein boost regimen elicits a 
higher quality antibody response than those elicited by other regimens. The parameters 
for this assessment include the elicitation of a broader heterologous NAb response, the 
unique elicitation of antibodies to the CD4bs, and the elicitation of a higher avidity 
binding antibody response. These aspects are enhanced in sera from DNA prime-protein 
boosted individuals while still maintaining the ability to mediate other potentially 
relevant protective mechanisms, such as ADCC and complement activation. All of these 
parameters make the DNA prime-protein boost regimen a strong candidate for further 
vaccine development.  
Using the DNA plus protein regimen we were also able to demonstrate that even 
closely related gp120s will elicit a different heterologous NAb response. Using LN40 and 
B33 gp120s as model immunogens, we demonstrated that priming with LN40 gp120 
elicits a broader heterologous NAb response. Through the use of mutagenic epitope 
mapping, we implicated the elicitation of antibodies to the CD4bs in LN40 primed 
animals as the likely mechanism for this broader neutralization. The evidence presented 
here that not all gp120s are created immunogenically equal may have implications for the 
selection of antigen formulations in future vaccines. 
Additionally, we have also demonstrated that generation of mAbs from DNA 
primed-protein boosted rabbits is both feasible and provides a valuable tool for studying 
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the characteristics of antibody responses elicited through immunization. The mAbs 
generated here were targeted to a diverse set of epitopes within gp120, including 
functionally conserved ones such as the CD4bs and the V3 loop. While some these mAbs 
proved to have only a very narrow specificity, others cross reacted to every gp120 tested 
in this study. While only limited neutralization assays have been completed, we have 
observed and expect to continue to see that some mAbs generated in this study have the 
ability to neutralize heterologous isolates of HIV. Of the neutralizing antibodies that have 
been identified thus far, we found that they are targeted to multiple epitopes, which in the 
context of a polyclonal sera, could play either additive or synergistic roles in neutralizing 
heterologous isolates of HIV. Collectively, these results indicate that a DNA prime-
protein boost regimen elicits a high quality antibody response targeted to a diverse set of 
epitopes which, in some cases, is capable of mediating neutralization of diverse 
heterologous isolates. 
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